

CITATION REPORT

List of articles citing

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]

DOI: 10.1200/jco.2003.10.038

Journal of Clinical Oncology, 2003, 21, 2237-46.

Source: <https://exaly.com/paper-pdf/35398226/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2308	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. 2010 , 4, 178		12
2307	Amplified genes as therapeutic targets in cancer. 2003 , 2, 147-153		1
2306	Management of lung cancer in older adults. 2003 , 53, 325-41		77
2305	Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program. 2003 , 5, 182-6		4
2304	The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer. 2003 , 5 Suppl 1, S5-S10		2
2303	Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. 2003 , 5 Suppl 1, S11-7		8
2302	Molecular Targeted Agents in NonSmall-Cell Lung Cancer. 2003 , 5, S22-S28		11
2301	Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. 2003 , 126, 1597-602		62
2300	Discussion. 2003 , 126, 1601-1602		
2299	ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. 2003 , 89, 246-7		40
2298	Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. 2003 , 89 Suppl 2, S9-14		25
2297	Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. 2003 , 89 Suppl 2, S19-23		20
2296	Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. 2003 , 22, 6629-38		80
2295	Pharmacogenomics: road to anticancer therapeutics nirvana?. 2003 , 22, 6621-8		48
2294	Clinical benefit in NSCLC: the evidence for gefitinib (Iressa®ZD1839). 2003 , 1, 17-22		2
2293	Successful treatment of persistent bronchorrhea by gefitinib in a case with Recurrent Bronchioloalveolar Carcinoma: a case report. 2003 , 1, 8		17
2292	Adjuvant systemic therapies in early-stage non-small-cell lung cancer. 2003 , 5 Suppl 1, S29-35		1

2291	Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention. 2003 , 5 Suppl 1, S36-40		12
2290	Symptoms and quality of life: important patient outcomes?. 2003 , 1, 23-28		
2289	Getting to grips with gefitinib. 2003 , 4, 719-20		1
2288	Targeting the epidermal growth factor receptor: prognostic and clinical implications. 2003 , 1, 9-15		4
2287	Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3718-20	2.2	11
2286	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. 2003 , 290, 2149-58		2093
2285	Gefitinib (ZD1839, Iressa®): a selective epidermal growth factor receptor-tyrosine kinase inhibitor. 2003 , 9, 151-160		4
2284	Gefitinib therapy for advanced non-small-cell lung cancer. 2003 , 37, 1644-53		9
2283	Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. 2003 , 8, 576-86		58
2282	Activation of tyrosine kinases in cancer. 2003 , 8, 531-8		152
2281	Opportunities and challenges in the development of kinase inhibitor therapy for cancer. 2003 , 17, 2998-3010		130
2280	Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. 2003 , 89, 1827-9		61
2279	Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib. 2003 , 89 Suppl 2, S15-8		36
2278	Conclusion. 2003 , 89, S24-S24		78
2277	Extensive experience of disease control with gefitinib and the role of prognostic markers. 2003 , 89 Suppl 2, S3-8		46
2276	The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts. 2003 , 89 Suppl 2, S1-35		3
2275	Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil. 2003 , 89, 585-92		69
2274	Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2227-9	2.2	43

2273	Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3798-807	2.2	1166
2272	Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?. 2003 , 95, 1813-5		7
2271	Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. 2003 , 8, 501-14		25
2270	Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?. 2003 , 42, 926-7		3
2269	Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. 2003 , 10, 388-95		33
2268	Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. 2003 , 60, S16-21		1
2267	ErbB-targeted therapeutic approaches in human cancer. 2003 , 127-135		
2266	Bortezomib Gefitinib. 2003 , 38, 733-736		
2265	[Targeted molecular therapy: the example of Iressa (ZD1839)]. 2003 , 19, 1052-4		0
2264	Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer. 2004 , 61, 889-98		5
2263	[Molecular therapy in lung cancer]. 2004 , 61, 365-71		2
2262	Receptor tyrosine kinases and inhibitors in lung cancer. 2004 , 4, 589-604		28
2261	[Predicting response to Iressa: unexpected mechanism]. 2004 , 20, 750-1		0
2260	Clinical Development Issues. 2004 , 287-306		1
2259	Epidermal growth factor receptor inhibitors in lung cancer therapy. 2004 , 25 Suppl 1, 17-27		7
2258	Inhibition of epidermal growth factor receptor and symptom improvement in advanced non-small cell lung cancer. 2004 , 25 Suppl 1, 29-32		
2257	Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. 2004 , 4, 5-17		37
2256	Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. 2004 , 4, 569-83		5

2255	Signaling multiplex of the epidermal growth factor receptor. 2004 , 4, 1145-56		2
2254	The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. 2004 , 1, 2-3		15
2253	Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. 2004 , 15, 1042-7		281
2252	Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3003-15	2.2	291
2251	HER1/EGFR targeting: refining the strategy. 2004 , 9, 58-67		91
2250	Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4646-8	2.2	48
2249	Gefitinib: a new agent in palliative care. 2004 , 21, 222-7		4
2248	TTF-1, Cytokeratin 7, 34 β E12, and CD56/NCAM Immunostaining in the Subclassification of Large Cell Carcinomas of the Lung. 2004 , 122, 884-893		85
2247	Lung cancer in US women: a contemporary epidemic. 2004 , 291, 1763-8		185
2246	Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo. <i>Clinical Cancer Research</i> , 2004 , 10, 5940-8	12.9	36
2245	Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4966-70	2.2	30
2244	Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. <i>Clinical Cancer Research</i> , 2004 , 10, 7311-7	12.9	61
2243	Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2004 , 10, 3216-24	12.9	137
2242	Twenty-five years of treating advanced NSCLC: what have we achieved?. 2004 , 15 Suppl 4, iv81-3		11
2241	Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. <i>Clinical Cancer Research</i> , 2004 , 10, 4607-13	12.9	56
2240	Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 136-43	12.9	132
2239	Phase II trial of gefitinib in recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 133-42	2.2	607
2238	Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 759-61	2.2	63

2237	Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. 2004 , 15, 786-92		47
2236	Clinical pharmacology and determinates of response to gefitinib in non-small cell lung cancer. 2004 , 10, 169-175		
2235	Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. 2004 , 96, 1133-41		333
2234	Pharmacological background of EGFR targeting. 2004 , 15, 1007-12		77
2233	Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 8613-9	12.9	17
2232	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. <i>Clinical Cancer Research</i> , 2004 , 10, 8195-203	12.9	458
2231	Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 6006-12	12.9	36
2230	Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4383-8	12.9	71
2229	Quality of life issues in non-small cell lung cancer. 2004 , 4, 215-26		3
2228	Molecularly targeted therapy: have the floodgates opened?. 2004 , 9, 357-60		43
2227	Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. 2004 , 9, 471-8		6
2226	Racial disparity of epidermal growth factor receptor expression in prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4725-9	2.2	77
2225	Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). 2004 , 13, 3029-43		139
2224	Brain metastasis responding to gefitinib alone. 2004 , 67, 174-8		32
2223	Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). 2004 , 16 Suppl 4, 104-7		11
2222	Mutations in the EGFR: the importance of genotyping. 2004 , 3, 434-5		7
2221	Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. 2004 , 15, 33-7		30
2220	Imatinib: Paradigm or Anomaly?. 2004 , 3, 831-833		11

2219	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. 2004 , 1, 27-34		4
2218	Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. <i>Journal of Clinical Oncology</i> , 2004 , 22, 785-94	2.2	1508
2217	Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4442-5	2.2	200
2216	A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 7812-9	12.9	94
2215	Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4874-84	12.9	66
2214	Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. 2004 , 96, 990-7		192
2213	Targeting the epidermal growth factor receptor. 2004 , 91, 418-24		126
2212	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004 , 101, 13306-11		3659
2211	Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. 2004 , 91, 208-12		180
2210	Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. 2004 , 91 Suppl 2, S1-2		15
2209	Lung cancer: a cost and outcome study based on physician practice patterns. 2004 , 7, 112-23		15
2208	Abstracts. 2004 , 22, 1-104		
2207	Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. 2004 , 34, 901-15		36
2206	In vitro metabolism of gefitinib in human liver microsomes. 2004 , 34, 983-1000		48
2205	Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. 2004 , 15, 419-26		121
2204	Targeting targeted therapy. 2004 , 350, 2191-3		119
2203	Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. 2004 , 96, 715; author reply 715-6		6
2202	New directions in oncology nursing care: focus on gefitinib in patients with lung cancer. 2004 , 8, 385-92		3

2201	Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?. 2004 , 96, 1117-9	34
2200	Gefitinib, a novel, orally administered agent for the treatment of cancer. 2004 , 29, 95-103	55
2199	Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. 2004 , 151, 238-41	140
2198	An image worth a thousand lives?. 2004 , 22, 677-8	3
2197	Selecting the right patient for tumor therapy. 2004 , 10, 577-8	21
2196	Gefitinib--a novel targeted approach to treating cancer. 2004 , 4, 956-65	283
2195	Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). 2004 , 90, 82-6	46
2194	Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. 2004 , 90, 566-72	66
2193	Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. 2004 , 90, 1563-71	17
2192	Epidermal growth factor receptor tyrosine kinase inhibitors. 2004 , 90, 2250-5	89
2191	Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. 2004 , 91 Suppl 2, S11-7	21
2190	Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells. 2004 , 91, 1964-9	45
2189	A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. 2004 , 91, 1996-2004	151
2188	'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). 2004 , 14, 33-40	55
2187	Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer. 2004 , 5, 331-2	
2186	2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004. 2004 , 6, 11-6	
2185	Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. 2004 , 5, 411-5	68
2184	[New pharmacological strategies for the treatment of cancer]. 2004 , 28, 167-80	1

2183	A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. 2004 , 31, 83-92	15
2182	Gefitinib: phase II and III results in advanced non-small cell lung cancer. 2004 , 31, 93-9	18
2181	Targeting the HER-kinase axis in cancer. 2004 , 31, 9-20	53
2180	Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. 2004 , 31, 3-8	33
2179	Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. 2004 , 31, 23-30	16
2178	Drug development in patients with advanced non-small cell lung cancer and poor performance status. 2004 , 31, 21-6	16
2177	Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. 2004 , 31, 27-31	11
2176	Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. 2004 , 40, 43-51	39
2175	Evaluation of safety and efficacy of gefitinib ('Iressa', ZD1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. 2004 , 4, 51	27
2174	The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. 2004 , 4, 83	42
2173	Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. 2004 , 6, 123-8	124
2172	Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. 2004 , 6, 154-61	11
2171	Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. 2004 , 6 Suppl 1, S7-S19	29
2170	Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. 2004 , 6 Suppl 1, S30-4	15
2169	Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs. 2004 , 6 Suppl 1, S35-42	8
2168	Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. 2004 , 6 Suppl 1, S43-7	3
2167	Current development of adjuvant treatment of non-small-cell lung cancer. 2004 , 6 Suppl 2, S63-70	4
2166	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). 2004 , 68, 135-44	48

2165	Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. 2004 , 68, 1453-64	80
2164	Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. 2004 , 5, 525-31	82
2163	Targeting cell cycle and apoptosis for the treatment of human malignancies. 2004 , 16, 670-8	87
2162	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004 , 350, 2129-39	9266
2161	A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. 2004 , 445, 255-62	50
2160	Acute gefitinib-induced pneumonitis. 2004 , 9, 406-9	20
2159	Chemoradiotherapy for lung cancer: current status and perspectives. 2004 , 9, 435-43	17
2158	Review of epidermal growth factor receptor biology. 2004 , 59, 21-6	859
2157	Perspectives of cellular and molecular neurosurgery. 2004 , 70, 255-69	12
2156	Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. 2004 , 101, 1733-44	7
2155	Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells. 2004 , 201, 97-105	45
2154	Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs. 2004 , 39, 183-94	16
2153	Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. 2004 , 58, 941-9	44
2152	Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. 2004 , 58, 991-1002	51
2151	Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer. 2004 , 59, 39-43	4
2150	The role of targeted therapy in non-small cell lung cancer. 2004 , 51, 29-44	21
2149	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. 2004 , 50, 175-86	7
2148	The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. 2004 , 13, 1569-77	61

2147	American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. <i>Journal of Clinical Oncology</i> , 2004 , 22, 330-53	2.2	1154
2146	Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. 2004 , 64, 9093-100		132
2145	An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. 2004 , 64, 9139-43		224
2144	Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3238-47	2.2	922
2143	Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1103-9	2.2	670
2142	Novel treatments in non-small cell lung cancer. 2004 , 18, 245-67		10
2141	[Targeted therapies in thoracic oncology]. 2004 , 21, 527-37		1
2140	Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients*1. 2004 ,		
2139	Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. 2004 ,		
2138	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa[ZD1839]). 2004 , 68, 135-135		
2137	[Treatment of non-small cell lung cancer (2003 update)]. 2004 , 21, 175-8		0
2136	Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. 2004 , 50, 175-175		
2135	Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. 2004 , 46, 255-61		157
2134	Place des th�rapeutiques cibl�es : les inhibiteurs des r��cepteurs tyrosine kinases. 2004 , 60, 68-71		
2133	[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targeting]. 2004 , 21, 881-5		0
2132	[Prediction of response to tyrosine kinase epithelial cell growth factor receptor inhibitors: a major breakthrough in the treatment of non-small-cell lung cancer]. 2004 , 60, 252-3		
2131	[French experience of gefitinib in non-small cell bronchial carcinoma]. 2004 , 21, 934-42		1
2130	Biomarkers in cancer management: a crucial bridge toward personalized medicine. 2004 , 1, 305-311		1

2129	Targeted therapies for cancer [from tamoxifen to gefitinib (Iressa)] 2004 , 1, 411-416	2
2128	Management of non-small cell lung cancer in elderly patients. 2004 , 2, 15-25	1
2127	New targets and new treatments in non-small cell lung cancer. 2004 , 2, 1-6	1
2126	New perspectives in the management of non-small cell lung cancer (NSCLC): Gefitinib (Iressa, ZD 1839). 2004 , 2, 34-39	1
2125	Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. 2004 , 43, 317-22	45
2124	Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. 2004 , 44, 221-30	185
2123	Severe myelotoxicity in a combination of gefitinib and vinorelbine. 2004 , 45, 121-3	16
2122	Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. 2004 , 45, 93-104	158
2121	Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. 2004 , 45, 221-5	15
2120	Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. 2004 , 45, 255-62	6
2119	Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. 2004 , 45, 381-6	138
2118	The biology of non-small-cell lung cancer: identifying new targets for rational therapy. 2004 , 46, 135-48	31
2117	Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. 2004 , 46, 247-54	50
2116	Invited Abstracts:. 2004 , 46, S1-S30	
2115	Therapy of advanced non-small-cell lung cancer (take home message). 2004 , 45 Suppl 2, S259-62	2
2114	New targeted treatments in lung cancer--overview of clinical trials. 2004 , 45 Suppl 2, S199-208	11
2113	Signal transduction pathways as novel therapy targets in lung cancer. 2004 , 45 Suppl 2, S177-86	4
2112	Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer. 2004 , 27, 1081-92	62

2111	Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. 2004 , 64, 2475-92		19
2110	Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. 2004 , 5, 274-89		12
2109	Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy. 2004 , 6, 85-98		43
2108	Adjuvant therapy of resected non-small-cell lung cancer. 2004 , 6, 162-9		8
2107	Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. 2004 , 5 Suppl 2, S67-74		6
2106	Bronchoalveolar carcinoma: current treatment and future trends. 2004 , 6 Suppl 2, S75-9		3
2105	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. 2004 , 64, 8919-23		1059
2104	Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. <i>Journal of Clinical Oncology</i> , 2004 , 22, 777-84	2.2	1496
2103	Méthodologie d'évaluation des thérapies ciblées dans les essais cliniques. perspectives d'avenir. 2004 , 60, 72-78		
2102	Cancer bronchique non à petites cellules avancé demain, de nouvelles alternatives efficaces ?. 2004 , 60, 20-27		
2101	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. 2004 , 351, 337-45		4112
2100	Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer. 2004 , 30, 655-9		1
2099	Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1alpha in non-small cell lung cancers. 2004 , 214, 157-64		31
2098	New cancer therapeutics: target-specific in, cytotoxics out?. 2004 , 7, 79-87		17
2097	Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. 2004 , 40, 667-72		27
2096	Targeted therapy--how successful has it been?. 2004 , 40, 2016-21		1
2095	Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients. 2004 , 40, 1776-86		15
2094	Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?. 2004 , 40, 1807-9		9

2093	Bone forming adenocarcinoma with pulmonary metastasis arising from the parotid gland. 2004 , 40, 46-49	
2092	Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. 2004 , 63, 619-24	17
2091	Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. 2004 , 10, 481-6	251
2090	Targeted therapy for malignant gliomas. 2004 , 11, 807-18	23
2089	Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. 2004 , 34, 917-34	100
2088	Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. 2004 , 305, 1163-7	1400
2087	Epidermal growth factor receptor in tumor angiogenesis. 2004 , 18, 1007-21, viii	130
2086	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004 , 304, 1497-500	7937
2085	Growth factor receptors as targets for lung cancer therapy. 2004 , 16, 3-12	15
2084	Acute lung injury as an adverse event of gefitinib. 2004 , 15, 461-7	38
2083	Therapy for Stage IIIA, IIIB and IV Non-Small Cell Lung Cancer. 2004 , 11, 161-174	
2082	Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas. 2004 , 54, 1480-8; discussion 1488-9	32
2081	Session 5: Signalling Networks in Tumorigenesis. 2004 , 32, 737-738	
2080	Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (Iressa/ZD1839). 2004 , 12, 1053	4
2079	Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial. 2004 , 16, 392-9	10
2078	Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview. 2004 , 16 Suppl 4, 36-40	8
2077	The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. 2004 , 29, e1-8	188
2076	Targeted therapies in the treatment of non small cell lung cancer: reality and hopes. 2004 , 16, 126-9	7

2075	The role of EGFR inhibitors in nonsmall cell lung cancer. 2004 , 16, 130-5	76
2074	Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases. 2004 , 43, 718-20	28
2073	Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer?, ?, ??Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial [INTACT 2]. J Clin Oncol 2004;22:7859-64.. 2004 , 30, 655-659	
2072	Clinical Symposium. 2004 , 16, 69-98	3
2071	Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. 2005 , 65, 3003-10	98
2070	Targeting cytokine receptors and pathways in the treatment of breast cancer. 2005 , 126, 243-62	
2069	Treatment of locally advanced non-small cell lung cancer in the elderly. 2005 , 17, 130-4	5
2068	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. 2005 , 17, 123-9	7
2067	Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. 2005 , 128, 3975-84	88
2066	Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities. 2005 , 28, 467-70	
2065	Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. 2005 , 70, 73-81	34
2064	EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm. 2005 , 12, 47-52	2
2063	Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. 2005 , 16, 739-42	2
2062	Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report. 2005 , 16, 747-9	6
2061	Treatment of non-small cell lung cancer and targeted therapies: where are we?. 2005 , 17, 114-7	1
2060	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. 2005 , 17, 118-22	54
2059	The treatment of advanced non-small cell lung cancer. 2005 , 11, 287-91	41
2058	EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. 2005 , 29, 633-9	206

2057	Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase. 2005 , 433-450	0
2056	Neutropenic enterocolitis in lung cancer: a report of two cases and a review of the literature. 2005 , 44, 467-70	13
2055	Development of Precise Pharmacodiagnostic (PharmDx) Tests for Molecular Targeted Therapies. 2005 , 38, 209-216	1
2054	Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. 2005 , 17, 679-84	18
2053	Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. 2005 , 128, 317-21	101
2052	11,11'-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity. 2005 , 16, 515-24	43
2051	Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 2005 , 28, 481-6	25
2050	The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. 2005 , 11, 209-16	29
2049	Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. 2005 , 11, 417-24	57
2048	New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. 2005 , 16, 211-21	26
2047	Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer. 2005 , 16, 1123-8	23
2046	Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program. 2005 , 16, 191-8	7
2045	Simultaneous bilateral spontaneous pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple lung metastases. 2005 , 44, 862-4	22
2044	Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. 2005 , 23, 73-7	32
2043	Evolving molecular-based targeted therapy for cancer: an exciting field. 2005 , 31, 299-305	
2042	Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. 2005 , 19, 385-93	37
2041	Low vitamin B6 levels are associated with white matter lesions in Alzheimer's disease. 2005 , 53, 1073-4	19
2040	Acupuncture for dysphagia in poststroke patients: a videofluoroscopic study. 2005 , 53, 1083-4	25

2039	Hyperimmunoglobulin a and celiac disease in the elderly. 2005 , 53, 1074-5	2
2038	Effects of physical exercise on plasma concentrations of sex hormones in elderly women with dementia. 2005 , 53, 1076-7	3
2037	Racial differences in pressure ulcer prevalence in nursing homes. 2005 , 53, 1077-8	7
2036	Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?. 2005 , 53, 1078-80	
2035	Treatment of valproate-induced hyperammonemia. 2005 , 53, 1080	7
2034	Functional assessment and infectious diseases. 2005 , 53, 1080-2	6
2033	An elderly man with multiple hepatic lesions: other concepts on amebic liver abscess. 2005 , 53, 1082	0
2032	Therapeutic approaches in metastatic renal cell carcinoma. 2005 , 95, 1153-61	13
2031	Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. 2005 , 21, 321-39	39
2030	A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. 2005 , 92, 15-20	58
2029	Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). 2005 , 92, 1711-9	122
2028	Role of novel targeted therapies in the clinic. 2005 , 92 Suppl 1, S21-7	11
2027	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. 2005 , 93, 23-8	45
2026	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. 2005 , 93, 1334-40	70
2025	Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. 2005 , 19, 729-38	48
2024	The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. 2005 , 24, 4433-41	110
2023	Pseudodiarrhea caused by vaginal pessary in an elderly patient. 2005 , 53, 1083	18
2022	A warm bath. 2005 , 53, 1075-6	

2021	Targeted therapies for non-small cell lung cancer. 2005 , 59, 1055-62	13
2020	2004 Highlights From: 29th European Society of Medical Oncology Congress Vienna, Austria October 29 through November 2, 2004. 2005 , 6, 272-275	
2019	Updated data from the Iressa survival in lung cancer trial. 2005 , 6, 340-2	2
2018	Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer. 2005 , 7, 163-5	3
2017	Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. 2005 , 6, 214-6	1
2016	Redefining bronchioloalveolar carcinoma. 2005 , 32, 329-35	20
2015	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
2014	Are more aggressive therapies able to improve treatment of locally advanced non-small cell lung cancer: combined modality treatment?. 2005 , 32, S25-34	7
2013	Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 2005 , 32, S35-41	23
2012	Other compounds and targets in non-small cell lung cancer. 2005 , 32, S30-6	5
2011	An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer. 2005 , 32, S3-8	79
2010	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. 2005 , 32, S9-15	69
2009	A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. 2005 , 6, 343-9	16
2008	Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. 2005 , 7, 127-32	29
2007	An approach to evaluating drug-nutrient interactions. 2005 , 25, 1789-800	46
2006	Recent advances and future perspectives in the management of lung cancer. 2005 , 42, 540-610	1
2005	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2005 , 205, 355-63	26
2004	Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. 2005 , 113, 109-15	139

2003	Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer. 2005 , 113, 510-1	81
2002	Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. 2005 , 116, 36-44	119
2001	Absence of the ERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients. 2005 , 116, 652-3	5
2000	Laminin 5 expression protects against anoikis at aerogenous spread and lepidic growth of human lung adenocarcinoma. 2005 , 116, 876-84	31
1999	High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. 2005 , 103, 2344-8	188
1998	Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. 2005 , 103, 2566-74	67
1997	Targeted agents for the treatment of advanced renal cell carcinoma. 2005 , 104, 2323-33	96
1996	Chronic myeloid leukemia: a model for oncology. 2005 , 84, 487-97	43
1995	A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers. 2005 , 56, 557-62	8
1994	[Molecular target structures in oncology]. 2005 , 46, 847-8, 850-4, 856-60	2
1993	[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. 2005 , 100, 785-93	2
1992	Neue molekulare Therapiekonzepte beim Mammakarzinom. 2005 , 38, 432-438	
1991	Blockade of epidermal growth factor receptor (EGFR) activity. 2005 , 53, 179-92	17
1990	Perspektiven der Targeted therapy 2005 , 2, 268-275	
1989	Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. 2005 , 446, 483-8	89
1988	Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer. 2005 , 131, 783-8	8
1987	Molekulare Diagnostik bei nicht-hämatologischen malignen Erkrankungen. 2005 , 11, 873-888	
1986	Clinical review of Iressa for the treatment of NSCLC. 2005 , 2, 829-833	

1985	Gefitinib therapy for non-small cell lung cancer. 2005 , 6, 75-81		19
1984	Targeted therapies for gynecologic malignancies. 2005 , 6, 121-32		2
1983	Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 2005 , 7, 241-7		21
1982	Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient. 2005 , 71, 277-80		14
1981	Metastatic tumors of the nervous system. 2005 , 75, 1-3		11
1980	A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. 2005 , 89, 165-72		138
1979	EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. 2005 , 22, 1757-61		17
1978	A Case of Adenocarcinoma of the Lung Successfully Treated With Alternate Day Administration of Gefitinib. 2005 , 45, 833-837		
1977	PharmaForum. 2005 , 28, 670-671		
1976	Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer. 2005 , 128, 308-16		18
1975	The role of EGFR-TK inhibition in non-small cell lung cancer. 2005 , 28, 619-20		1
1974	Lung Cancer Chemotherapy for Radiation Oncologists. 2005 , 135-154		
1973	An Epidermal Growth Factor Receptor Intron 1 Polymorphism in Healthy Women in Poland. 2005 , 20, 184-188		3
1972	Targeted therapies for esophageal cancer. 2005 , 10, 590-601		114
1971	Practical management of patients with non-small-cell lung cancer treated with gefitinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 165-74	2.2	150
1970	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. 2005 , 65, 1459-70		249
1969	Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. 2005 , 97, 499-506		124
1968	Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3288-93	2.2	60

1967	Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. 2005 , 65, 7525-9		130
1966	Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. <i>Clinical Cancer Research</i> , 2005 , 11, 5668-70	12.9	24
1965	Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?. 2005 , 97, 868-9		21
1964	Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. <i>Clinical Cancer Research</i> , 2005 , 11, 3032-7	12.9	113
1963	Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. 2005 , 2, e13		17
1962	Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. 2005 , 16, 1817-23		25
1961	Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. 2005 , 16, 1867-73		19
1960	Pharmacogenomics steps toward personalized medicine. 2005 , 2, 325-337		60
1959	Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. 2005 , 65, 9176-84		157
1958	Improving cancer therapeutics by molecular profiling. 2005 , 6, 553-68		2
1957	Receptor tyrosine kinases and anticancer therapy. 2005 , 11, 1139-49		36
1956	Epidermal Growth Factor. 2005 ,		
1955	HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. 2005 , 65, 4253-60		97
1954	EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. <i>Clinical Cancer Research</i> , 2005 , 11, 2924-9	12.9	112
1953	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2005 , 11, 5539-48	12.9	234
1952	Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 3750-7	12.9	269
1951	Drug interaction between gefitinib and warfarin. 2005 , 35, 478-82		20
1950	Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. <i>Clinical Cancer Research</i> , 2005 , 11, 1572-8	12.9	75

1949	Italian clinical research in non-small-cell lung cancer. 2005 , 16 Suppl 4, iv110-115		3
1948	Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. <i>Clinical Cancer Research</i> , 2005 , 11, 1983-9	12.9	114
1947	Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance. 2005 , 11, 429-34		14
1946	Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. 2005 , 65, 11631-8		339
1945	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3227-34	2.2	343
1944	HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. 2005 , 16, 538-48		39
1943	Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. <i>Clinical Cancer Research</i> , 2005 , 11, 8105-8	12.9	120
1942	One hundred years of lung cancer. 2005 , 172, 523-9		267
1941	Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3235-42	2.2	183
1940	Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 5300-9	12.9	87
1939	The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1349-57	6.1	145
1938	Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 641-9	6.1	102
1937	Gefitinib in colorectal cancer: if wishes were horses. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5446-9	2.2	15
1936	Inhibitors of growth factor signalling. 2005 , 12 Suppl 1, S183-7		43
1935	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. 2005 , 16, 1906-14		52
1934	Lung cancer in women. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3212-8	2.2	121
1933	Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib. <i>Clinical Cancer Research</i> , 2005 , 11, 8872-9	12.9	29
1932	Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2534-43	2.2	336

1931	HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. 2005 , 10, 345-56		232
1930	Medical treatment of non-small-cell lung cancer. 2005 , 16 Suppl 2, ii229-32		5
1929	How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. 2005 , 10 Suppl 2, 23-9		20
1928	Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?. 2005 , 58, 700-4		79
1927	Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5323-33	2.2	286
1926	Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2946-54	2.2	97
1925	Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company. 2005 , 127, 385-8		
1924	[Non-small-cell lung cancer third-line therapy with gefitinib]. 2005 , 59, 321-7		1
1923	Factors predicting response to EGFR tyrosine kinase inhibitors. 2005 , 26, 314-22		18
1922	Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. 2005 , 26, 342-52		18
1921	Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. 2005 , 237, 342-7		71
1920	Epidermal growth factor receptor inhibitors in cancer treatment. 2005 , 1, 221-34		49
1919	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. 2005 , 5, 727-35		2
1918	Clinical advancement of EGFR inhibitors in cancer therapy. 2006 , 327, 189-202		6
1917	A man whose scapula was spared a drug-associated rash. 2005 , 172, 745		10
1916	Erlotinib in the treatment of non-small cell lung cancer. 2005 , 5, 767-75		18
1915	The future of adjuvant chemotherapy for resected non-small cell lung cancer. 2005 , 5, 165-75		8
1914	Assessment of Epidermal Growth Factor Receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. 2005 , 4, 1381-6		33

1913	Gefitinib in non-small cell lung cancer. 2005 , 6, 985-93			41
1912	Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. 2005 , 92, 1877-80			16
1911	ZD6474--clinical experience to date. 2005 , 92 Suppl 1, S14-20			55
1910	Targeted antitumour therapy--future perspectives. 2005 , 92 Suppl 1, S28-31			12
1909	Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. 2005 , 92, 1063-8			43
1908	EGFR inhibitors: what have we learned from the treatment of lung cancer?. 2005 , 2, 554-61			69
1907	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. 2005 , 97, 339-46			1919
1906	Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. 2005 , 102, 7665-70			827
1905	Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 4289-94	12.9		107
1904	Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2005 , 11, 8418-24	12.9		201
1903	Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. 2005 , 65, 3555-61			138
1902	Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6172-80	2.2		92
1901	Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. <i>Clinical Cancer Research</i> , 2005 , 11, 7480-9	12.9		82
1900	Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 921-2; author reply 922	2.2		4
1899	ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. 2005 , 102, 3788-93			437
1898	Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. 2005 , 97, 1185-94			268
1897	Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6838-45	2.2		513
1896	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. 2005 , 10, 855-74			8

1895	Molecularly-targeted therapies for non-small cell lung cancer. 2005 , 6, 2667-79		5
1894	Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8531-3	2.2	27
1893	Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5235-46	2.2	430
1892	Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 455-60	2.2	170
1891	Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7738-40	2.2	32
1890	Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 235-7	2.2	10
1889	Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. 2005 , 65, 9868-75		112
1888	Impact of molecular pathology on the clinical management of lung cancer. 2005 , 72, 229-32		4
1887	In Reply:. <i>Journal of Clinical Oncology</i> , 2005 , 23, 922-922	2.2	1
1886	Therapeutic targeting of receptor tyrosine kinases in lung cancer. 2005 , 9, 533-59		20
1885	Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. <i>Clinical Cancer Research</i> , 2005 , 11, 1368-71	12.9	124
1884	Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer. 2005 , 1, 51-61		1
1883	Epithelial membrane protein-1 is a biomarker of gefitinib resistance. 2005 , 102, 11858-63		74
1882	Therapy of breast cancer with molecular targeting agents. 2005 , 16 Suppl 4, iv28-36		35
1881	Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. <i>Clinical Cancer Research</i> , 2005 , 11, 2300-4	12.9	221
1880	Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8786-93	2.2	172
1879	Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. 2005 , 4, 822-30		25
1878	Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. 2005 , 128, 947-57		59

1877	Lung cancer in women: emerging differences in epidemiology, biology, and therapy. 2005 , 128, 370-81	120
1876	Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. 2005 , 69, 224-38	13
1875	Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis. 2005 , 34, 48-50	6
1874	Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program. 2005 , 28, 195-8	7
1873	Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. 2005 , 68, 538-47	37
1872	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients. 2005 , 28, 623-7	3
1871	[EGF receptor blockade with monoclonal antibodies and so-called "small molecules"]. 2005 , 28 Suppl 4, 18-24	5
1870	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 2005 , 1, 461-6	6
1869	Strategies for enhanced radiation delivery in patients with lung cancer. 2005 , 2, 103-13	3
1868	Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?. 2005 , 4, 1096-7	4
1867	Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. 2005 , 4, 818-21	9
1866	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). 2005 , 366, 1527-37	1802
1865	Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. <i>Clinical Cancer Research</i> , 2005 , 11, 2879-82	12.9 227
1864	Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. 2005 , 6, 383-91	170
1863	Optimizing chemotherapy and targeted agent combinations in NSCLC. 2005 , 50, S25-S32	17
1862	Managing cutaneous side effects of epidermal growth factor receptor (HER1/EGFR) inhibitors. 2005 , 2, 492-496	9
1861	Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?. 2005 , 68, 160-1	0
1860	Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer. 2005 , 68, 183-6	15

1859	Targeted therapy for non-small cell lung cancer. 2005 , 17, 199-204		8
1858	Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. 2005 , 50, 375-84		136
1857	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8081-92	2.2	551
1856	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6829-37	2.2	641
1855	The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. 2005 , 16, 1334-42		78
1854	Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5007-18	2.2	333
1853	Erlotinib in lung cancer - molecular and clinical predictors of outcome. 2005 , 353, 133-44		1594
1852	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. 2005 , 97, 643-55		1367
1851	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2513-20	2.2	839
1850	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2493-501	2.2	681
1849	Race, gender and mutations in the prediction of anti-EGFR activity. 2005 , 1, 201-4		
1848	Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 2106-10	12.9	133
1847	Current imaging paradigms in radiation oncology. 2005 , 163, 1-25		51
1846	Le cancer bronchique chez la femme. 2005 , 22, 55-62		2
1845	Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale. 2005 , 19, 389-420, viii		35
1844	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. 2005 , 7, 396-403		200
1843	Lung: Medical Oncology. 2005 , 16, P8-P11		
1842	Erlotinib in non-small cell lung cancer: a review. 2005 , 6, 995-1002		8

1841	Perspectives on novel therapies for bronchial carcinoma. 2005 , 6, 1157-67		5
1840	Cytochrome P450-dependent metabolism of gefitinib. 2005 , 35, 39-50		107
1839	Second-generation kinase inhibitors. 2005 , 9, 975-93		48
1838	Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. 2005 , 23, 296-302		16
1837	Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5900-9	2.2	1250
1836	An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. 2005 , 6, 2855-66		8
1835	State of the art in therapy for non-small cell lung cancer. 2005 , 23, 427-42		58
1834	Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2445-59	2.2	613
1833	Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. 2005 , 5, 101-12		11
1832	Spotlight on gefitinib in non-small-cell lung cancer. 2005 , 5, 133-6		4
1831	EGFR pharmacogenomics: the story continues to mutate and evolve. 2005 , 5, 137-9		1
1830	Receptor-targeted cancer therapy. 2005 , 24, 271-82		27
1829	Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. <i>Clinical Cancer Research</i> , 2005 , 11, 5878-85	12.9	295
1828	Predictors of the response to gefitinib in refractory non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 2244-51	12.9	161
1827	Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. 2005 , 16, 780-5		69
1826	Role of tyrosine kinase inhibitors in cancer therapy. 2005 , 315, 971-9		713
1825	Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. 2005 , 44, 717-22		13
1824	Nano neodymium oxide induces massive vacuolization and autophagic cell death in non-small cell lung cancer NCI-H460 cells. 2005 , 337, 52-60		133

1823	Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. 2005 , 41, 1286-90	44
1822	Antitumor activity of HER-2 inhibitors. 2005 , 227, 9-23	77
1821	Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. 2005 , 225, 61-74	13
1820	Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer. 2005 , 230, 33-46	32
1819	Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. 2005 , 226, 37-47	42
1818	Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. 2005 , 99, 298-307	13
1817	Interstitial lung disease in lung cancer: separating disease progression from treatment effects. 2005 , 28, 103-13	52
1816	Single-dose clinical pharmacokinetic studies of gefitinib. 2005 , 44, 1165-77	112
1815	Epidermal Growth Factor Receptor as a Target for Chemotherapy. 2005 , 5, S19-S27	47
1814	Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. 2005 , 5 Suppl 2, S101-6	22
1813	Computer-assisted image analysis of bronchioloalveolar carcinoma. 2005 , 6, 281-6	10
1812	Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. 2005 , 47, 129-38	118
1811	Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. 2005 , 47, 253-9	51
1810	Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?. 2005 , 47, 325-36	18
1809	Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. 2005 , 47, 421-3	18
1808	Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. 2005 , 48, 141-4	36
1807	Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial. 2005 , 48, 267-73	42
1806	Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. 2005 , 48, 365-77	19

1805	Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. 2005 , 49, 225-31	44
1804	Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. 2005 , 49, 417-8	3
1803	Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. 2005 , 49, 337-43	150
1802	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. 2005 , 50, 1-8	105
1801	Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib. 2005 , 50, 107-14	7
1800	Consensus on medical treatment of non-small-cell lung cancer—Update 2004. 2005 , 50, 129-137	2
1799	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. 2005 , 50, 259-63	8
1798	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. 2005 , 50, 25-33	70
1797	Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. 2005 , 50, 417-8	29
1796	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. 2005 , 352, 786-92	3250
1795	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. 2005 , 353, 2012-24	1211
1794	Novel therapies in lung cancer. 2005 , 19, 343-67, vii	4
1793	Epidemiology of lung cancer: looking to the future. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3175-85	2.2 336
1792	Inhibitors of Protein Kinases and Protein Phosphates. 2005 ,	1
1791	Current Advancements in Hard-To-Treat Cancers. 2005 , 4, 105-113	0
1790	The Importance of Balancing Toxicity and Efficacy in Chemotherapy. 2005 , 4, 127-136	1
1789	Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?. 2005 , 4, 71-84	28
1788	Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. 2005 , 92, 1110-6	58

1787	Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 6816-22	12.9	125
1786	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2556-68	2.2	525
1785	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. 2005 , 45, 357-84		107
1784	Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. 2005 , 50, 393-9		15
1783	Erlotinib in previously treated non-small-cell lung cancer. 2005 , 353, 123-32		4590
1782	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. 2005 , 7, R570-9		94
1781	Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. 2006 , 29, 572-4		80
1780	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. 2006 , 95, 998-1004		244
1779	Breast Cancer and Molecular Medicine. 2006 ,		2
1778	Dissimilarity in gene expression profiles of lung adenocarcinoma in Japanese men and women. 2006 , 3, 223-35		1
1777	The place of targeted therapies in the management of non-small cell bronchial carcinoma. 2006 , 23, 137-147		2
1776	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. 2007 , 60, 881-4		31
1775	Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. 2006 , 95, 1070-5		41
1774	Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. 2006 , 95, 1483-9		148
1773	Cancer Drug Resistance. 2006 ,		17
1772	Epidermal growth factor receptor as a major anticancer drug target. 2006 , 10, 877-88		6
1771	Three case reports of hand-foot syndrome with gefitinib. 2006 , 24, 514-6		8
1770	Should every lung cancer patient be tested for EGFR mutation?. 2006 , 10, 789-91		1

1769	Is EGFR expression important in non-small cell lung cancer?. 2006 , 61, 98-9		33
1768	The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. 2006 , 6, 531-44		13
1767	Cancer therapies targeted to the epidermal growth factor receptor and its family members. 2006 , 16, 147-164		3
1766	The wind of change in the therapy of lung cancer. 2006 , 6, 469-72		
1765	Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. 2006 , 11, 274-84		78
1764	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5034-42	2.2	623
1763	Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3340-6	2.2	449
1762	Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. 2006 , 36, 344-50		25
1761	Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. 2006 , 52, 47-52		44
1760	A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. 2006 , 36, 69-75		61
1759	First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 64-9	2.2	147
1758	Where next for gefitinib in patients with lung cancer?. 2006 , 7, 499-507		101
1757	Targeted Therapy in Oncology. 2006 , 62, 169-73		2
1756	Est-il nécessaire de sélectionner les patients pour prescrire des thérapies ciblées dans les cancers bronchiques non petites cellules de stade IV ?. 2006 , 62, 41-44		
1755	Clinical trials in a molecular world. 2006 , 16, 681-94, ix		3
1754	Novel therapies targeting signaling pathways in lung cancer. 2006 , 16, 379-96, vi		10
1753	La place des thérapies ciblées dans la prise en charge des CBNPC. 2006 , 23, 148-157		
1752	Novel targeted therapies for non-small cell lung cancer. 2006 , 16, 353-66		1

1751	[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer]. 2006 , 23, 149-51	1
1750	CBNPC stade IV. 2006 , 23, 78-83	1
1749	Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. 2006 , 45, 633-44	54
1748	Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. 2006 , 66, 1441-63	11
1747	Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. 2006 , 6, 59-65	9
1746	Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. 2006 , 8, 22-9	19
1745	Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. 2006 , 8, 99-109	6
1744	Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. 2006 , 7 Suppl 4, S111-7	25
1743	Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. 2006 , 7 Suppl 4, S118-25	14
1742	Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. 2006 , 8 Suppl 1, S31-5	22
1741	Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2158-63	2.2 127
1740	A review of erlotinib and its clinical use. 2006 , 7, 177-93	53
1739	Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. 2006 , 40, 261-9	140
1738	A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. 2006 , 51, 115-21	27
1737	Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. 2006 , 51, 71-7	49
1736	Second-line treatment for advanced non-small cell lung cancer: a systematic review. 2006 , 51, 159-72	41
1735	Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. 2006 , 51, 89-96	49
1734	EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. 2006 , 51, 363-8	65

1733	PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. 2006 , 51, 297-301	82
1732	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. 2006 , 52, 75-81	9
1731	Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. 2006 , 52, 93-7	84
1730	Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. 2006 , 52, 99-103	20
1729	Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. 2006 , 52, 135-40	72
1728	A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. 2006 , 52, 305-11	8
1727	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. 2006 , 53, 117-21	53
1726	Efficacy and safety of gefitinib in chemo-naïve patients with advanced non-small cell lung cancer treated in an Expanded Access Program. 2006 , 53, 331-7	10
1725	Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. 2006 , 53, 157-64	20
1724	Gefitinib is of more benefit in chemotherapy-naïve patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. 2006 , 53, 339-45	15
1723	Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. 2006 , 53, 387-90	31
1722	L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. 2006 , 54, 103-8	29
1721	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. 2006 , 53, 311-22	64
1720	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. 2006 , 54, 201-7	31
1719	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. 2006 , 54, 193-9	32
1718	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. 2006 , 54, 387-98	88
1717	Integrating new targeted agents into the treatment of non-small-cell lung cancer. 2006 , 54 Suppl 2, S25-31	5
1716	Second-line therapeutic options in non-small-cell lung cancer. 2006 , 54 Suppl 2, S15-8	4

1715	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. 2006 , 66, 944-50		446
1714	Newer developments in immunohistology. 2006 , 59, 1117-26		28
1713	A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. 2006 , 22, 561-73		77
1712	Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2549-56	2.2	305
1711	Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?. <i>Clinical Cancer Research</i> , 2006 , 12, 5919-20	12.9	2
1710	Gefitinib prevents bleomycin-induced lung fibrosis in mice. 2006 , 174, 550-6		86
1709	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. <i>Clinical Cancer Research</i> , 2006 , 12, 4283-7	12.9	142
1708	A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. 2006 , 94, 1599-603		33
1707	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. 2006 , 10, 306-15		34
1706	Prognostic biomarkers in non-small-cell lung carcinoma. 2006 , 12, 418-428		7
1705	Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors. 2006 , 60, 629-32		5
1704	Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. 2006 , 234, 73-80		55
1703	High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. 2006 , 239, 292-7		22
1702	Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?. 2006 , 32, 630-6		26
1701	Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. 2006 , 42, 17-23		133
1700	Targeted kinase inhibitors in lung cancer: from EGFR to patients. 2006 , 42, 124-5		
1699	(CA)n microsatellite polymorphism of ERBB-1 in breast cancer. 2006 , 42, 1698-701		2
1698	Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. 2006 , 37, 542-6		90

1697	Interstitial lung disease associated with gefitinib. 2006 , 100, 698-704	30
1696	100 years of lung cancer. 2006 , 100, 2073-84	90
1695	Emerging dermatologic issues in the oncology patient. 2006 , 25, 179-89	13
1694	EGFR as a target: rationale for therapy. 2006 , 22, 5-9	11
1693	Clinical experience with anti-EGFR therapy. 2006 , 22, 10-9	11
1692	Epidermal growth factor receptor pathway inhibitors. 2006 , 1, 299-310	5
1691	Drugs for Lung Cancer Treatment. 2006 , 60, 123	
1690	Epidermal growth factor receptor-targeted agents for lung cancer. 2006 , 13, 129-40	16
1689	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. 2006 , 1, 847-855	101
1688	Novel mutations of epidermal growth factor receptor in localized prostate cancer. 2006 , 11, 2518-25	35
1687	Current Update on the Management of Locally Advanced Non-small Cell Lung Cancer. 2006 , 5, 1	
1686	Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. 2006 , 119, 63-68	6
1685	Bronchioloalveolar Carcinoma of the Lung. 2006 , 313-320	
1684	Contemporary Issues in the Systemic Treatment of Lung Cancer. 99-119	
1683	The Trend Toward Personalized Medicine. 2006 ,	
1682	[Drug-induced lung diseases]. 2006 , 127, 425-32	5
1681	Non-Small-Cell Lung Cancer. 2006 ,	
1680	EGF receptor testing for non-small cell lung carcinomas. 2006 , Chapter 10, Unit 10.9	1

1679	Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. 2006 , 331, 139-49	10
1678	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. 2006 , 1, 520-525	21
1677	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. 2006 , 1, 984-990	27
1676	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. 2006 , 15, 1205	2
1675	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. 2006 , 1, 31-37	16
1674	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	24
1673	Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. 2006 , 1, 1042-1058	34
1672	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. 2006 , 1, 413-416	34
1671	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?. 2006 , 1, 684-691	4
1670	Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. 2006 , 16, 533	1
1669	Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. 2006 , 29, 615-23	6
1668	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 582-587	7
1667	EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naïve non-small cell lung cancer. 2006 , 1, 260-7	60
1666	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	
1665	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. 2006 , 1, 367-376	28
1664	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. 2006 , 1, 1002-1009	48
1663	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. 2006 , 1, 847-855	140
1662	Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group. 2006 , 1, 447-453	5

1661	A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. 2006 , 129, 1031-8	75
1660	Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma. 2006 , 1, 413-416	54
1659	Rational Development of Targeted Cancer Therapies Using Biomarkers. 2006 , 37, 482-489	
1658	Investigating the molecular basis of drug action and response: chemocentric genomics and proteomics. 2006 , 7, 387-95	5
1657	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. 2006 , 1, 545-550	2
1656	Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. 2006 , 1, 231-9	102
1655	Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. 2006 , 1, 1042-1058	64
1654	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. 2006 , 1, 520-525	29
1653	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. 2006 , 1, 965-971	11
1652	A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. 2006 , 15, 101-8	28
1651	Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes. 2006 , 12, 33-9	21
1650	Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. 2006 , 1, 417-424	5
1649	A Literature Review of Molecular Markers Predictive of Clinical Response to Cytotoxic Chemotherapy in Patients with Lung Cancer. 2006 , 1, 31-37	13
1648	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. 2006 , 1, 984-990	30
1647	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). 2006 , 1, 1-13	38
1646	Matching patients with drugs: triumphs and challenges. 2006 , 3, 335-344	2
1645	New developments in chemotherapy for advanced non-small cell lung cancer. 2006 , 18, 156-61	8
1644	Antiangiogenic drugs in non-small cell lung cancer treatment. 2006 , 18, 151-5	17

1643	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. 2006 , 18, 609-14	3
1642	Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIb or IV) non-small-cell lung cancer. 2006 , 17, 401-9	117
1641	Aspirin reduces adverse effects of gefitinib. 2006 , 17, 423-7	15
1640	New molecular targeted therapies in thyroid cancer. 2006 , 17, 869-79	17
1639	Targeted therapies and non-small-cell lung cancer: work in progress?. 2006 , 18, 132-4	2
1638	Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. 2006 , 18, 144-50	7
1637	Advances in chemotherapy of non-small cell lung cancer. 2006 , 130, 1211-9	139
1636	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. 2006 , 83-132	1
1635	Effect of gefitinib on brain metastases from non-small cell lung cancer. 2006 , 46, 504-7	8
1634	Management of transitional cell carcinoma by targeting the epidermal growth factor receptor. 2006 , 3, 407-416	
1633	Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. 2006 , 46, 614-23	43
1632	Gefitinib is effective against juvenile pilocytic astrocytoma in vitro. 2006 , 47, 293-8	5
1631	Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. 2006 , 11, 113-6	16
1630	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. 2006 , 11, 287-91	6
1629	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. 2006 , 11, 687-92	27
1628	Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. 2006 , 11, 693-8	18
1627	Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. 2006 , 13, 587-92	47
1626	Molecular medicine, the Medicare drug benefit, and the need for cost control. 2006 , 54, 1442-6	9

1625	The management of PS2 patients with advanced non-small cell lung cancer. 2006 , 60, 1493-6	2
1624	Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. 2006 , 2, 22-31	1
1623	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. 2006 , 17, 3-9	10
1622	The role of pharmacogenetics in cancer therapeutics. 2006 , 62, 35-46	54
1621	New targets and challenges in the molecular therapeutics of cancer. 2006 , 62, 5-14	27
1620	SUC102 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells. 2006 , 97, 84-9	15
1619	Recent trends in the treatment of advanced lung cancer. 2006 , 97, 448-52	16
1618	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. 2006 , 97, 753-9	64
1617	Comparing antibody and small-molecule therapies for cancer. 2006 , 6, 714-27	531
1616	Impact of genetic diagnostics on drug development strategy. 2006 , 5, 459-62	10
1615	Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. 2006 , 94, 85-92	57
1614	Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. 2006 , 94, 631-6	80
1613	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 2006 , 94, 896-903	117
1612	EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. 2006 , 95, 1390-5	110
1611	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. 2006 , 19, 986-98	16
1610	Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. 2006 , 25, 1205-15	111
1609	Epidermal growth factor receptor directed therapy in head and neck cancer. 2006 , 57, 25-43	44
1608	Non-small-cell lung cancer in the elderly. 2006 , 57, 183-90	5

1607	Is tailored therapy feasible in oncology?. 2006 , 57, 79-101		16
1606	Clinical experience with gefitinib: an update. 2006 , 58, 31-45		46
1605	Multitargeted therapy: can promiscuity be praised in an era of political correctness?. 2006 , 59, 150-8		24
1604	In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. 2006 , 16, 1969-74		64
1603	Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib. 2006 , 18, 573-4		0
1602	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. 2006 , 80, 136-45		169
1601	Lung Cancer. 2006 , 552-628		1
1600	Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. 2006 , 23, 161-70		36
1599	Interpreting disparate responses to cancer therapy: the role of human population genetics. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2151-7	2.2	40
1598	Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. 2006 , 24, 117-23		10
1597	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. 2006 , 24, 291-7		60
1596	Targeting growth factors and angiogenesis; using small molecules in malignancy. 2006 , 25, 279-92		22
1595	Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib. 2006 , 132, 719-25		15
1594	Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. 2007 , 133, 93-102		17
1593	Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. 2006 , 11, 243-5		34
1592	Current status and perspective of angiogenesis and antivasular therapeutic strategy: non-small cell lung cancer. 2006 , 11, 73-81		21
1591	Current topics and the clinical effects of target-based antineoplastic agents. 2006 , 11, 164-6		1
1590	Biological and clinical implications of EGFR mutations in lung cancer. 2006 , 11, 190-8		169

1589	Resistance to gefitinib. 2006 , 11, 487-91	26
1588	Cancer management can be personalized? [Cancer genomic research in China. 2006 , 5, 156-158	2
1587	Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. 2006 , 33 Suppl 1, 1-5	10
1586	A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. 2006 , 57, 533-9	48
1585	Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. 2006 , 58, 577-84	38
1584	Impact of EGFR mutations on treatment of non-small cell lung cancer. 2006 , 58, 5-9	3
1583	Defining clinically relevant molecular subsets of lung cancer. 2006 , 58 Suppl 1, s11-5	16
1582	Molecular classification of tumors with special reference to EGFR mutation in lung cancer. 2006 , 58, 17-23	6
1581	The impact and role of EGFR gene mutation on non-small cell lung cancer. 2006 , 58, 25-31	7
1580	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. 2006 , 58, 33-37	1
1579	[Therapy strategies for advanced renal cell carcinoma]. 2006 , 45, 99-110, quiz 111-2	5
1578	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. 2006 , 1, 23-33	1
1577	Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. 2006 , 1, 13-22	1
1576	Aims and difficulties of targeting. 2006 , 1, 69-70	
1575	Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring. 2006 , 1, 114-122	
1574	Second- and third-line treatments in non-small cell lung cancer. 2006 , 7, 37-49	15
1573	Emerging approaches to advanced bronchioloalveolar carcinoma. 2006 , 7, 69-76	4
1572	Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. 2006 , 101, 18-23	27

1571	Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. 2006 , 18, 2089-97	233
1570	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. 2006 , 1766, 217-29	27
1569	Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase. 2006 , 71, 1422-34	68
1568	Geographic variation in the second-line treatment of non-small cell lung cancer. 2006 , 33, S39-44	6
1567	Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies. 2006 , 33, S17-24	7
1566	Use of novel second-line targeted therapies in non-small cell lung cancer. 2006 , 33, S9-16	21
1565	Second-line treatment options in advanced non-small cell lung cancer: current status. 2006 , 33, S3-8	7
1564	Epidermal growth factor receptor targeting in cancer. 2006 , 33, 369-85	560
1563	Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer. 2006 , 6, 288	5
1562	Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. 2006 , 7, 250-6	68
1561	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. 2006 , 7, 326-31	27
1560	Gefitinib monotherapy in chemotherapy-naïve patients with inoperable stage III/IV non-small-cell lung cancer. 2006 , 7, 406-11	31
1559	Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. 2006 , 8 Suppl 1, S7-14	78
1558	Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. 2006 , 8 Suppl 1, S15-22	12
1557	Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. 2006 , 97, 724-34	56
1556	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. 2006 , 107, 1207-18	153
1555	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. 2006 , 107, 1866-72	3
1554	Survival outcome and predictors of gefitinib antitumor activity in East Asian chemo-naïve patients with advanced nonsmall cell lung cancer. 2006 , 107, 1873-82	51

1553	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. 2006 , 107, 2858-65	45
1552	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. 2006 , 118, 963-9	130
1551	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. 2006 , 118, 257-62	507
1550	Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. 2006 , 119, 2557-66	99
1549	Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. 2006 , 81, 349-54	8
1548	Is the Importance of Achieving Stable Disease Different between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Cytotoxic Agents in the Second-Line Setting for Advanced Non-small Cell Lung Cancer?. 2006 , 1, 684-691	11
1547	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. 2006 , 3, 170-1	16
1546	Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. 2006 , 84, 42-8	29
1545	Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. 2006 , 66, 11389-98	98
1544	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. 2006 , 17, 981-5	101
1543	Point mutations of protein kinases and individualised cancer therapy. 2006 , 7, 2243-61	23
1542	Expression biomarkers for clinical efficacy and outcome prediction in cancer. 2006 , 7, 105-15	10
1541	Recent Clinical Trials in Non-Small Cell Lung Cancer. 2006 , 2, 81-99	
1540	Der Einfluss genetischer Polymorphismen auf die Wirksamkeit von Medikamenten unter besonderer Berücksichtigung onkologischer Therapien. 2006 , 38, 16-21	
1539	Tumorspezifische Therapien auch auf der Palliativstation? - Eine alte Frage neu beleuchtet. 2006 , 7, 19-24	1
1538	Can reproductive pattern explain better survival of women with lung cancer?. 2006 , 45, 47-53	13
1537	Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. 2006 , 6, 271-94	27
1536	Editorial. 2006 , 2, 1-1	

1535	Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1807-13	2.2	134
1534	Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. 2006 , 36, 29-39		23
1533	Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes. 2006 , 36, 523-6		10
1532	Targeting the EGFR pathway for cancer therapy. 2006 , 13, 3483-92		157
1531	Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. 2006 , 17 Suppl 7, vii109-14		83
1530	Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2659-65	2.2	131
1529	Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. 2006 , 4, 521-8		119
1528	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3078-84	12.9	85
1527	Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. 2006 , 11, 655-65		42
1526	Update on epidermal growth factor receptor mutations in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7232-41	12.9	315
1525	Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 306-14	2.2	138
1524	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1154-65	6.1	79
1523	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. 2006 , 98, 1714-23		93
1522	Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. 2006 , 36, 269-73		19
1521	Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. <i>Clinical Cancer Research</i> , 2006 , 12, 43-8	12.9	173
1520	Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. <i>Clinical Cancer Research</i> , 2006 , 12, 7117-25	12.9	104
1519	Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. 2006 , 126, 608-15		130
1518	Molecular on/off switch. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4940-2	2.2	11

1517	Exercise induced bronchoconstriction in elite athletes: measuring the fall. 2006 , 61, 94-6		14
1516	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. 2007 , 44, 166-72		37
1515	Expanding role of chemotherapy in lung cancer. 2006 , 17 Suppl 10, x101-7		2
1514	Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5025-33	2.2	133
1513	Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. <i>Clinical Cancer Research</i> , 2006 , 12, 4645-51	12.9	31
1512	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2006 , 12, 839-44	12.9	597
1511	Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. <i>Clinical Cancer Research</i> , 2006 , 12, 617-25	12.9	77
1510	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. 2006 , 17, 450-6		185
1509	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. 2007 , 29, 128-33		11
1508	Second-line chemotherapy for non-small cell lung cancer. 2006 , 17 Suppl 5, v68-71		8
1507	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Clinical Cancer Research</i> , 2006 , 12, 4416s-4420s	12.9	113
1506	Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. 2006 , 61, 140-5		102
1505	Erlotinib-induced breast cancer regression. 2006 , 40, 2043-7		13
1504	Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer. 2006 , 36, 12-6		4
1503	Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment. 2006 , 57-66		
1502	Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. 2006 , 11, 358-73		54
1501	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1679-88	2.2	257
1500	Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?. <i>Clinical Cancer Research</i> , 2006 , 12, 4409s-4415s	12.9	44

1499	Targeted therapies in combination with chemotherapy in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4451s-4457s	12.9	16
1498	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. <i>Clinical Cancer Research</i> , 2006 , 12, 4403s-4408s	12.9	68
1497	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. <i>Clinical Cancer Research</i> , 2006 , 12, 5764-9	12.9	526
1496	High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). 2006 , 59, 255-9		31
1495	Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. <i>Clinical Cancer Research</i> , 2006 , 12, 6186-93	12.9	71
1494	Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. 2006 , 17 Suppl 2, ii46-48		20
1493	Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. 2006 , 66, 7708-15		34
1492	Chemoresistance in solid tumours. 2006 , 17 Suppl 10, x315-24		127
1491	PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. 2006 , 66, 5346-53		58
1490	Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. <i>Clinical Cancer Research</i> , 2006 , 12, 3652-6	12.9	54
1489	Women and lung cancer. 2006 , 17 Suppl 2, ii79-82		4
1488	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Clinical Cancer Research</i> , 2006 , 12, 3908-14	12.9	479
1487	Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. 2006 , 66, 981-8		64
1486	Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1689-99	2.2	69
1485	Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. 2006 , 98, 1739-42		218
1484	Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. <i>Clinical Cancer Research</i> , 2006 , 12, 2538-44	12.9	215
1483	Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. 2006 , 70, 285-9		59
1482	Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3831-7	2.2	255

1481	The new drugs advent: clinical or economic outcomes?. 2006 , 17 Suppl 2, ii88-90		1
1480	Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3213-4; author reply 3214-5	2.2	24
1479	Important bias in the Astragalus meta-analysis. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3215-6; author reply 3216-7	2.2	5
1478	In Reply. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3214-3215	2.2	7
1477	Genomic approaches to lung cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4384s-4391s	12.9	40
1476	Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. <i>Clinical Cancer Research</i> , 2006 , 12, 5659-67	12.9	180
1475	Lung cancer genetics and pharmacogenomics. 2006 , 115, 298-302		2
1474	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. 2006 , 17 Suppl 2, ii42-45		23
1473	Novel targeted approaches in non-small cell lung cancer (NSCLC). 2006 , 17 Suppl 5, v91-3		3
1472	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. 2006 , 17, 1120-7		75
1471	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. 2006 , 2, 67-72		
1470	The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. <i>Clinical Cancer Research</i> , 2006 , 12, 4372s-4376s	12.9	68
1469	Non-small cell lung cancer: second-line and beyond. 2006 , 17 Suppl 10, x97-100		6
1468	Treatment of advanced non-small cell lung cancer. 2006 , 17 Suppl 2, ii36-41		23
1467	Chemotherapy of advanced NSCLC in special patient population. 2006 , 17 Suppl 5, v72-8		13
1466	Gefitinib: an adverse effects profile. 2006 , 5, 469-79		32
1465	The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. 2006 , 25, 246-51		11
1464	Epidermal growth factor receptor inhibition and non-small cell lung cancer. 2006 , 43, 291-323		14

1463	Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. 2006 , 4, 971-81		30
1462	Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. 2006 , 3, 256-68		105
1461	A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy. 2006 , 6, 1411-9		1
1460	HER2 expression as a potential marker for response to therapy targeted to the EGFR. 2006 , 94, 1144-53		28
1459	131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. 2006 , 21, 5-14		30
1458	Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. 2006 , 103, 2316-21		436
1457	Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. 2006 , 11, 602-11		27
1456	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. 2006 , 8, 137-44		68
1455	Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1612-9	2.2	181
1454	Clinical Trials for Lung Cancer in Progress in Japan. 2006 , 463-469		
1453	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2007 , 12, 325-30		54
1452	Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. 2007 , 83, 793-802		26
1451	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. 2007 , 7, 821-36		9
1450	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. <i>Clinical Cancer Research</i> , 2007 , 13, 2795-803	12.9	222
1449	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3936-44	2.2	105
1448	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2642-51	6.1	47
1447	Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer. 2007 , 71, 508-18		23
1446	Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1683-91	6.1	234

1445	Targeting HER proteins in cancer therapy and the role of the non-target HER3. 2007 , 97, 453-7		215
1444	Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. 2007 , 97, 183-93		27
1443	New targets for non-small-cell lung cancer therapy. 2007 , 7, 1423-37		33
1442	Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. <i>Clinical Cancer Research</i> , 2007 , 13, s4597-601	12.9	33
1441	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). 2007 , 96, 1047-51		156
1440	'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. 2007 , 97, 1560-6		66
1439	Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. 2007 , 97, 494-501		62
1438	The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. <i>Clinical Cancer Research</i> , 2007 , 13, 5170-5	12.9	28
1437	Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. 2007 , 37, 725-9		35
1436	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. 2007 , 18 Suppl 9, ix150-5		12
1435	Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?. 2007 , 5, 87-101		2
1434	Optimizing Anti-EGFR Strategies in Cancer Treatment. 2007 , 3, 267-275		
1433	Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 523-31	12.9	19
1432	Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 6518-26	12.9	20
1431	PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. <i>Clinical Cancer Research</i> , 2007 , 13, 378-81	12.9	108
1430	Targeted therapies for non-small cell lung cancer. 2007 , 13, 2810-31		13
1429	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. 2007 , 12, 211-20		43
1428	Targeted therapy of breast cancer. 2007 , 13, 497-517		24

1427	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. 2007 , 99, 838-46		258
1426	A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2007 , 13, 1216-23	12.9	67
1425	Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. <i>Clinical Cancer Research</i> , 2007 , 13, 5150-5	12.9	252
1424	Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. 2007 , 131, 1628-34		95
1423	Review of targeted cancer therapies for the palliative care provider: Part 1: small molecules. 2007 , 15, 171-176		
1422	A translational view of the molecular pathogenesis of lung cancer. 2007 , 2, 327-43		237
1421	Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. 2007 , 2, 537-43		32
1420	EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). 2007 , 2, 423-9		68
1419	Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. 2007 , 2, 335-48		3
1418	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. 2007 , 8, 1211-20		2
1417	Risk-based and diagnostics-linked personalized medicine for cancer. 2007 , 4, 33-43		3
1416	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. 2007 , 11, 1287-98		23
1415	Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. 2007 , 7, 666-73		18
1414	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. 2007 , 1, 203-7		2
1413	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. 2007 , 3, 277-83		28
1412	Recent advances in targeted therapy for non-small cell lung cancer. 2007 , 11, 245-57		24
1411	Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. 2007 , 28, 273-9		33
1410	Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. 2007 , 26, 178-85		17

1409	Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 7086-92	12.9	58
1408	Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. 2007 , 67, 7695-702		37
1407	A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. <i>Clinical Cancer Research</i> , 2007 , 13, 5869-75	12.9	109
1406	Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. 2007 , 67, 2046-53		133
1405	NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 5663-4	12.9	22
1404	Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. 2007 , 18, 317-23		474
1403	p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. 2007 , 67, 1163-9		80
1402	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. 2007 , 67, 11924-32		589
1401	Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2528-33	2.2	129
1400	Molecular correlates of gefitinib responsiveness in human bladder cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 277-85	6.1	56
1399	Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib. <i>Clinical Cancer Research</i> , 2007 , 13, 5385-90	12.9	89
1398	HKI-272 in non small cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, s4593-6	12.9	41
1397	The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. <i>Clinical Cancer Research</i> , 2007 , 13, 6555-60	12.9	149
1396	Targeted therapies in lung cancer. 2007 , 18 Suppl 9, ix135-42		32
1395	Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2504-5	2.2	5
1394	Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. <i>Clinical Cancer Research</i> , 2007 , 13, s4606-12	12.9	42
1393	Clairvoyance or reliable prediction of the future?. 2007 , 18, 407-8		2
1392	Current status and future of target-based therapeutics. 2007 , 7, 273-84		6

1391 Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. **2007**, 3, 236-241

1390 Pharmacogenomics of Non-Small Cell Lung Cancer. **2007**, 5, 228-234

1389 Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. **2007**, 3, 226-235

1388 Methodological Issues of Clinical Research with EGFR Inhibitors. **2007**, 3, 292-302

3

1387 Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. *Molecular Cancer Therapeutics*, **2007**, 6, 1079-88

6.1 28

1386 The potential of gender-specific tumor pharmacology. **2007**, 8, 271-4

1

1385 Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. **2007**, 2, S125-7

5

1384 Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). **2007**, 2, 299-305

51

1383 The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. **2007**, 2, 414-22

35

1382 Gender differences: implications for clinical trials and practice. **2007**, 2, S15-8

14

1381 Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. **2007**, 2, 402-7

56

1380 Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib. **2007**, 333, 221-5

27

1379 Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?. **2007**, 2, 160-5

17

1378 Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. **2007**, 2, 758-61

31

1377 EGFR targeting of solid tumors. **2007**, 14, 295-304

220

1376 Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. **2007**, 46, 1651-5

15

1375 Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. **2007**, 2, 632-7

57

1374 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. **2007**, 2, 430-9

159

1373	Pharmacology of Epidermal Growth Factor Inhibitors. 2007 , 22, 24-39	9
1372	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. 2007 , 22, 10-23	3
1371	Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report. 2007 , 29, 799-803	4
1370	Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. 2007 , 15, 242-7	2
1369	Targeted therapies and non-small-cell lung cancer: new developments. 2007 , 19, 75-7	3
1368	Signal Transduction Therapy: Challenges to Clinical Trial Design. 2007 , 2, 21-30	1
1367	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. 2007 , 2, 22-28	33
1366	Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). 2007 , 132, 306S-13S	42
1365	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). 2007 , 2007, 207-210	
1364	Ethnic Disparities in the Treatment of Stage I Non-Small Cell Lung Cancer. 2007 , 2007, 146-149	
1363	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. 2007 , 19, 98-102	20
1362	Proteomics in pediatric research and practice. 2007 , 54, 9-28	6
1361	Identification of EGFR mutations in esophageal cancer. 2007 , 33, 44-8	34
1360	Rational bases for the development of EGFR inhibitors for cancer treatment. 2007 , 39, 1416-31	95
1359	Targeting novel and established therapies for non-small cell lung cancer. 2007 , 250, 9-16	10
1358	Cellular responses to EGFR inhibitors and their relevance to cancer therapy. 2007 , 254, 165-77	121
1357	[Targeted therapies and radiotherapy in lung cancer]. 2007 , 11, 77-83	3
1356	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. 2007 , 58, 30-5	19

1355	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2248-55	2.2	198
1354	Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. 2007 , 12, 90-8		138
1353	Kinase Inhibitors for Cancer. 2007 , 183-220		1
1352	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. 2007 , 18, 752-60		232
1351	Phase II clinical trial of chemotherapy-naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 760-6	2.2	279
1350	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. 2007 , 18, 99-103		116
1349	Apoptosis, Senescence, and Cancer. 2007 ,		6
1348	Readministration of gefitinib in a responder after treatment discontinuation due to gefitinib-related interstitial lung disease: a case report. 2007 , 1, 138		14
1347	In Vivo Imaging of Cancer Therapy. 2007 ,		2
1346	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2890-6 ^{12.9}		527
1345	Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice. 2007 , 20, 246-251		1
1344	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. 2007 , 1, 183-91		2
1343	Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. 2007 , 12, 201-10		69
1342	Perspectives in adjuvant chemotherapy in NSCLC. 2007 , 1, 99-110		1
1341	Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. 2007 , 23, 1509-15		27
1340	The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale. 2007 , 25, 591-603		14
1339	Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma. 2007 , 25, 366-71		9
1338	Targeted agents: the rules of combination. <i>Clinical Cancer Research</i> , 2007 , 13, 5232-7	12.9	47

1337	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. 2007 , 16, 239-49		112
1336	Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. <i>Clinical Cancer Research</i> , 2007 , 13, 799-805	12.9	50
1335	Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3266-73	2.2	44
1334	Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis. 2007 , 7, 77-86		15
1333	Small molecule signal transduction inhibitors for the treatment of solid tumors. 2007 , 25, 347-65		12
1332	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 587-95	2.2	515
1331	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4270-7	2.2	254
1330	[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer]. 2007 , 27, 353-63		6
1329	[New biological treatments for lung cancer]. 2007 , 63, 20-8		1
1328	[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?]. 2007 , 63, 147-54		0
1327	Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non [petites cellules (CBNPC). 2007 , 24, 120-124		5
1326	Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash. 2007 , 4, 198-202		5
1325	Les inhibiteurs de tyrosine kinase de l'EGFR dans le traitement du CBNPC. 2007 , 24, 188-197		1
1324	Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial. 2007 , 55, 101-7		5
1323	Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). 2007 , 55, 125-7		4
1322	Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. 2007 , 55, 115-21		25
1321	Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial. 2007 , 56, 371-6		4
1320	Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. 2007 , 56, 383-9		121

1319	Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. 2007 , 57, 193-200	18
1318	Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. 2007 , 57, 359-64	118
1317	Validation of the functional assessment of cancer therapy--lung symptom index-12 (FLSI-12). 2007 , 57, 339-47	13
1316	Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. 2007 , 58, 149-55	46
1315	Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. 2007 , 58, 414-7	31
1314	Gefitinib administration in a patient with lung cancer undergoing hemodialysis. 2007 , 58, 422-4	12
1313	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. 2007 , 5, 203-20	323
1312	Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. 2007 , 72, 234-42	21
1311	[Biologic therapy: current and future applications in oncology]. 2007 , 129, 184-93	3
1310	Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. 2007 , 6, 63	48
1309	Epidermal growth factor receptor inhibitors in non-small cell lung cancer. 2007 , 67, 1125-38	12
1308	EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. 2007 , 67, 2045-75	97
1307	Gefitinib Cytotoxicity in Non-small Cell Lung Cancer Cells is Enhanced by Low Dose Cisplatin Due to Ligand-independent EGFR Autophosphorylation. 2007 , 19, 155-164	
1306	Targeted Therapeutics in Cancer Treatment. 2007 , 117-148	
1305	Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. 2007 , 22, 393-9	9
1304	Sex-related Clinicopathologic Differences in Patients with Adenocarcinoma of the Lung. 2007 , 62, 203	
1303	Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer. 2007 , 2, S12-4	6
1302	Gefitinib-Related Interstitial Pneumonia. 2007 , 62, 134	

1301	Urinary Neopterin in Patients Treated with Gefitinib. 2007 , 18, 95-100	1
1300	Clinical and Preclinical Experience with Gefitinib and Sunitinib. 2007 , 2, 68-73	2
1299	Pharmacogenomics: clinical applications. 516-528	
1298	Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. 2007 , 28, 760-70	46
1297	Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. 2007 , 120, 1579-90	21
1296	Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. 2007 , 120, 781-7	130
1295	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. 2007 , 120, 1239-47	110
1294	Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. 2007 , 121, 1162-7	27
1293	Targeting cell signaling pathways for drug discovery: an old lock needs a new key. 2007 , 102, 580-92	107
1292	Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. 2007 , 210, 549-59	34
1291	Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. 2007 , 109, 1836-44	61
1290	Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. 2007 , 109, 1821-8	24
1289	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. 2007 , 110, 599-605	91
1288	Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. 2007 , 110, 581-9	221
1287	Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. 2007 , 110, 1321-8	18
1286	Response to dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. 2007 , 110, 2775-84	24
1285	Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. 2007 , 110, 2793-8	29
1284	Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. 2007 , 95, 63-9	29

1283	Metabolic functional imaging for tumor radiosensitivity monitoring. 2007 , 62, 227-39	13
1282	EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. 2007 , 62, 53-61	101
1281	Targeting mTOR signaling in lung cancer. 2007 , 63, 172-82	61
1280	Colorectal cancer therapeutics and the challenges of applied pharmacogenomics. 2007 , 31, 315-66	2
1279	Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients. 2007 , 19, 499-506	43
1278	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. 2007 , 49, 352-7	12
1277	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. 2007 , 26, 1567-76	71
1276	The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. 2007 , 26, 5023-7	94
1275	Epidermal growth factor receptor mutations in lung cancer. 2007 , 7, 169-81	2272
1274	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. 2007 , 96, 857-63	80
1273	Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. 2007 , 96, 1191-6	39
1272	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). 2007 , 97, 778-84	166
1271	Predictive markers in breast cancer--the future. 2008 , 52, 91-8	21
1270	Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients. 2007 , 16, 263-7	3
1269	Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. 2007 , 98, 246-52	88
1268	Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. 2007 , 98, 226-30	32
1267	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. 2007 , 98, 357-63	44
1266	GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2007 , 98, 1625-32	16

1265	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. 2007 , 98, 1817-24	469
1264	Systematic review: the application of molecular pathogenesis to prevention and treatment of oesophageal adenocarcinoma. 2007 , 25, 1253-69	22
1263	Mutational analysis of PTPRT phosphatase domains in common human cancers. 2007 , 115, 47-51	16
1262	Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. 2007 , 3, 66-78	14
1261	Epidermal growth factor receptor mutations in lung cancers. 2007 , 57, 233-44	60
1260	CCND1 messenger RNA expression is correlated with EGFR mutation status in lung cancer. 2007 , 8, 493-6	5
1259	Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. 2007 , 8 Suppl 2, S61-7	19
1258	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. 2007 , 7, 128	32
1257	Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. 2007 , 7, 150	41
1256	Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. 2007 , 7, 51	70
1255	The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib. 2007 , 570, 175-81	33
1254	Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). 2007 , 105, 132-7	80
1253	Targeted agents and esophageal cancer--the next step?. 2007 , 17, 62-9	21
1252	Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. 2007 , 141, 464-9	56
1251	The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. 2007 , 17, 1700-13	69
1250	Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. 2007 , 14, 942-53	112
1249	A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study. 2007 , 60, 53-9	1
1248	["Targeted Therapies" in NSCLC - present and future]. 2007 , 157, 545-53	

1247	Signalübermittlungsinhibitoren. 2007 , 13, 213-226	4
1246	Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. 2007 , 133, 169-76	13
1245	"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?". 2007 , 8, 28-37	16
1244	Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?. 2007 , 9, 255-64	17
1243	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. 2007 , 2, 3-12	9
1242	Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study. 2007 , 2, 63-71	1
1241	Lapatinib: a novel dual tyrosine kinase inhibitor. 2007 , 2, 107-112	2
1240	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. 2007 , 2, 145-151	3
1239	Molecular targeted therapy for advanced hepatocellular carcinoma. 2007 , 2, 199-210	6
1238	Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 2008 , 110, 127-34	16
1237	Targeted therapy for oesophageal cancer: an overview. 2008 , 27, 273-88	18
1236	Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. 2008 , 35, 1089-99	87
1235	Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer. 2008 , 62, 465-70	7
1234	Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?. 2008 , 63, 139-48	10
1233	Can we predict the response to epidermal growth factor receptor targeted therapy?. 2008 , 3, 87-99	1
1232	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. 2008 , 3, 173-186	3
1231	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. 2008 , 1, 101-108	
1230	The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC). 2008 , 9, 313-25	2

1229	EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. 2008 , 14, 39-43	34
1228	The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. 2008 , 25, 408-14	4
1227	Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients. 2008 , 13, 442-6	11
1226	Place des thérapeutiques biologiques ciblées. 2008 , 10, 540-544	
1225	EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. 2008 , 7, 440-446	1
1224	Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients. 2008 , 7, 677-681	
1223	Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. 2008 , 134, 569-77	55
1222	A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. 2008 , 134, 1371-6	9
1221	Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase. 2008 , 3, 1094-103	13
1220	Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. 2008 , 112, 1114-21	63
1219	Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. 2008 , 112, 2021-9	22
1218	Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. 2008 , 113, 826-33	87
1217	Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. 2008 , 113, 3199-208	74
1216	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. 2008 , 69, 359-372	34
1215	Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. 2008 , 122, 2612-20	39
1214	EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance. 2008 , 123, 2480-6	70
1213	Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. 2008 , 30, 863-7	86
1212	Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening. 2008 , 18, 285-8	31

1211	Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. 2008 , 15, 889-99	86
1210	Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases. 2008 , 28, 361-73	6
1209	Targeted therapy in the treatment of solid tumors: practice contradicts theory. 2008 , 73, 605-18	30
1208	Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. 2008 , 98, 1533-5	106
1207	A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). 2008 , 98, 716-9	5
1206	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). 2008 , 98, 907-14	175
1205	Emerging ethnic differences in lung cancer therapy. 2008 , 99, 1757-62	101
1204	Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. 2008 , 83, 477-84	44
1203	Selective targeting of the tumour vasculature. 2008 , 78, 955-67	10
1202	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. 2008 , 99, 303-8	34
1201	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. 2008 , 99, 929-35	198
1200	Exon 19 of EGFR mutation in relation to the CA-repeat polymorphism in intron 1. 2008 , 99, 1180-7	12
1199	N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. 2008 , 99, 1611-7	64
1198	Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation. 2008 , 99, 1679-84	13
1197	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. 2008 , 99, 1747-53	19
1196	Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. 2008 , 99, 2295-301	26
1195	Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. 2008 , 99, 2455-60	29
1194	A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. 2008 , 108, 42-6	101

1193	Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status. 2008 , 1, 102	6
1192	Induction chemotherapy with cisplatin, vinorelbine, and mitomycin-C followed by surgery for patients with pathologic N2 non-small-cell lung cancer. 2008 , 9, 44-50	2
1191	Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. 2008 , 9, 249-51	5
1190	Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. 2008 , 9 Suppl 3, S109-15	14
1189	Targeted agents in cancer therapy. 2008 , 36, 33-37	4
1188	Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. 2008 , 11, 1-15	276
1187	Cancer pharmacogenetics. 2008 , 448, 437-46	4
1186	Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. 2008 , 59, 81-7	16
1185	Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. 2008 , 59, 203-10	113
1184	Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. 2008 , 60, 175-82	65
1183	Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?. 2008 , 61, 73-81	21
1182	Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients. 2008 , 61, 328-39	41
1181	Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study. 2008 , 61, 378-84	8
1180	Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. 2008 , 61, 262-5	14
1179	The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis. 2008 , 62, 242-52	9
1178	Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. 2008 , 7, 33-43	46
1177	Multitargeted inhibitors in lung cancer: new clinical data. 2008 , 9 Suppl 3, S92-9	6
1176	siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. 2008 , 75, 2-8	18

1175	Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor. 2008 , 28, 295-306	5
1174	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. 2008 , 2, 167-78	39
1173	Molecular profiling of non-small cell lung cancer: of what value in clinical practice?. 2008 , 17, 451-62	1
1172	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
1171	Le traitement de la rechute d'un cancer bronchique non à petites cellules de stade IV. 2008 , 25, 3S113-3S118	
1170	Pharmacogenomics in drug discovery and development. Preface. 2008 , 448, v-vii	5
1169	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. 2008 ,	2
1168	Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. 2008 , 39, 316-23	19
1167	EGFR polymorphism of the kinase domain in Japanese lung cancer. 2008 , 148, 260-3	16
1166	Chemotherapeutic agents and the skin: An update. 2008 , 58, 545-70	185
1165	Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. 2008 , 85, 216-23	10
1164	EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. 2008 , 24, 27-33	9
1163	Therapeutic strategy for treatment of metastatic non-small cell lung cancer. 2008 , 42, 1640-52	22
1162	EGFR antagonists in cancer treatment. 2008 , 358, 1160-74	1570
1161	[Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies]. 2008 , 12, 14-24	5
1160	The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. 2008 , 34, 89-93	6
1159	Pharmacogenetics: improving drug and dose selection. 2008 , 8, 639-46	18
1158	Molecular-targeted therapies: lessons from years of clinical development. 2008 , 34, 61-80	41

1157	Advances in the treatment of non-small cell lung cancer. 2008 , 34, 521-6		6
1156	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. 2008 , 60 Suppl 2, S3-9		61
1155	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. 2008 , 60 Suppl 2, S10-8		16
1154	EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. 2008 , 60 Suppl 2, S23-30		42
1153	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. 2008 , 25, 288-94		13
1152	Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. 2008 , 20, 217-23		9
1151	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4268-75	2.2	600
1150	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2442-9	2.2	725
1149	Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. 2008 , 19, 739-45		32
1148	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. 2008 , 372, 1809-18		1067
1147	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1472-8	2.2	257
1146	Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. 2008 , 8, 129-38		92
1145	Molecular genetics of lung cancer in people who have never smoked. 2008 , 9, 676-82		100
1144	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. 2008 , 9, 962-72		623
1143	Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. 2008 , 26, 103-19, ix		39
1142	Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. 2008 , 26, 121-59, ix		23
1141	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2895-9	12.9	576
1140	Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. 2008 , 54, 463-74		25

1139	[Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer]. 2008 , 25, 1096-103			7
1138	Targeted therapy for solid tumors: current status. 2008 , 17, 279-301, vii-viii			10
1137	Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. 2008 , 59, 227-31			12
1136	EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. 2008 , 59, 429-42			120
1135	Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. 2008 , 9, 1321-37			3
1134	Implications of EGFR PharmDx kit for cetuximab eligibility. 2008 , 8, 141-8			15
1133	Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. 2008 , 10, 160-8			45
1132	First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. 2008 , 178, 847-53			57
1131	Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2450-6	2.2		467
1130	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5407-15	2.2		198
1129	Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. 2008 , 32, 924-30			95
1128	Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6317-23	12.9		53
1127	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. 2008 , 13, 1166-76			39
1126	Gefitinib: a consideration of cost. 2008 , 8, 223-32			
1125	Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?. 2008 , 13, 933-44			35
1124	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. <i>Clinical Cancer Research</i> , 2008 , 14, 957-60	12.9		110
1123	Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. <i>Clinical Cancer Research</i> , 2008 , 14, 6867-76	12.9		40
1122	A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6277-83	12.9		59

1121	Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. 2008 , 68, 3803-9		143
1120	Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. 2008 , 13, 1276-84		64
1119	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2008 , 3, S146-9		56
1118	Targeting growth factors in lung cancer. 2008 , 133, 1209-16		28
1117	The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. 2008 , 3, 1468-81		171
1116	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. 2008 , 19, 362-9		212
1115	Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4253-60	2.2	191
1114	Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4244-52	2.2	327
1113	Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. 2008 , 98, 154-60		90
1112	The role of gefitinib in the management of Asian patients with non-small cell lung cancer. 2008 , 17, 401-11		10
1111	Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1119-27	2.2	192
1110	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. <i>Clinical Cancer Research</i> , 2008 , 14, 6963-73	12.9	106
1109	Considerations for second-line therapy of non-small cell lung cancer. 2008 , 13 Suppl 1, 28-36		90
1108	¹⁸ F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2036-41	12.9	39
1107	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. 2008 , 68, 9479-87		522
1106	Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1135-41	2.2	63
1105	EGFR-targeting agents in oncology. 2008 , 18, 889-901		16
1104	Principles of Molecular Oncology. 2008 ,		1

1103	Other endpoints in screening studies for soft tissue sarcomas. 2008 , 13 Suppl 2, 27-31		19
1102	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. <i>Journal of Clinical Oncology</i> , 2008 , 26, 983-94	2.2	253
1101	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naïve non-small-cell lung cancer receiving first-line gefitinib monotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2745-53	2.2	222
1100	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. <i>Clinical Cancer Research</i> , 2008 , 14, 4877-82	12.9	242
1099	The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). <i>Clinical Cancer Research</i> , 2008 , 14, 5685-91	12.9	8
1098	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4418-25	2.2	71
1097	Carcinoma of the bronchus 60 years later. 2006 , 61, 1023-8		4
1096	Overview of gefitinib in non-small cell lung cancer: an Asian perspective. 2009 , 39, 137-50		50
1095	Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. 2008 , 13 Suppl 1, 14-20		67
1094	A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. 2008 , 129, 202-10		41
1093	[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. <i>Clinical Cancer Research</i> , 2008 , 14, 7423-9	12.9	136
1092	The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. <i>Clinical Cancer Research</i> , 2008 , 14, 2088-94	12.9	44
1091	Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1346-54	2.2	123
1090	MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. 2008 , 3, 331-9		168
1089	EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5589-95	2.2	180
1088	Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors. 2009 , 39, 116-23		15
1087	Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. 2008 , 38, 95-104		189
1086	Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. 2008 , 5, 268-78		77

1085	Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. 2008 , 17, 1013-28	41
1084	Somatic pharmacogenomics in cancer. 2008 , 8, 305-14	21
1083	Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung. 2008 , 359, 405-14	2
1082	Targeted therapy in advanced non-small-cell lung cancer. 2008 , 29, 291-301	24
1081	Speeding up the evaluation of new agents in cancer. 2008 , 100, 1204-14	109
1080	From nihilism to individualism: the evolution of lung cancer therapy. 2008 , 177, 1299-300	2
1079	Lung cancer and women. 2008 , 4, 705-16	12
1078	Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 599-606	6.1 59
1077	A phase II study of gefitinib in patients with advanced thyroid cancer. 2008 , 18, 317-23	162
1076	Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. 2008 , 3, 374-9	19
1075	Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. 2008 , 3, 1446-53	86
1074	Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib. 2008 ,	1
1073	Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. 2008 , 3, 250-7	61
1072	EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. 2008 , 3, 303-10	33
1071	First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. 2008 , 3, S143-5	19
1070	Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias. 2008 , 3, 467-71	32
1069	E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib. 2008 ,	
1068	A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. 2008 , 3, 386-93	78

1067	Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation. 2008 ,	
1066	Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. 2008 , 3, 832-9	115
1065	A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. 2008 , 3, 1166-71	40
1064	Recurrent gefitinib-induced interstitial lung disease. 2008 , 47, 533-6	22
1063	Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. 2008 ,	
1062	Clinical experience with gefitinib in Indian patients. 2008 , 3, 380-5	18
1061	Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. 2008 , 3, 1439-45	67
1060	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. 2008 , 3, 234-243	
1059	Principe des mécanismes d'action des thérapeutiques moléculaires ciblées en cancérologie pulmonaire. 2008 , 5, 1-16	
1058	Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. 2008 , 3, 400-4	53
1057	First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. 2008 , 3, S138-42	7
1056	Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. 2008 , 3, 912-4	36
1055	New directions in the management of advanced pancreatic cancer: a review. 2008 , 19, 435-46	32
1054	Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. 2008 , 31, 340-4	20
1053	A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 2008 , 19, 739-44	23
1052	Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. 2008 , 20, 162-75	39
1051	Advances in the Treatment of Metastatic Non-Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. 2008 , 15, 352-358	
1050	Cell signaling modifiers in prostate cancer. 2008 , 14, 40-5	7

1049 Biological treatments in cancer. 13-22

1048 HER1-4 expression status correlates with the efficacy of gefitinib treatment and tumor cell proliferative activity in non-small cell lung cancer. **2008**,

1047 Effects of gefitinib on radiation-induced lung injury in mice. **2008**, 75, 96-105

11

1046 Molecularly Targeted Therapy for Lung Cancer: Recent Topics. **2008**, 7, 1

2

1045 Clinical trial designs for more rapid proof-of-principle and approval. **2008**, 53-87

1

1044 New insights in drug development for the non-small cell lung cancer therapy. **2008**, 13, 5108-19

4

1043 Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. **2008**, 5, 209-17

57

1042 Targeted therapies in non-small cell lung cancer. **2008**, 8, 199-205

4

1041 EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. **2009**, 215

1040 Divide and conquer: progress in the molecular stratification of cancer. **2009**, 50, 464-73

4

1039 Clinical Proteomics and Molecular Pathology. **2009**, 165-183

2

1038 Two Cases of Lung Cancer with Carcinomatous Meningitis in Which Erlotinib Was Effective After Gefitinib Therapy. **2009**, 49, 207-213

1

1037 Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. **2009**, 24, 448-52

50

1036 Metastatic Bone Disease in Patients with Solid Tumors—Burden of Bone Disease and the Role of Zoledronic Acid. **2009**, 1, CMT.S1958

1035 [KRAS status versus EGFR status in lung cancer therapy]. **2009**, 96 Suppl, S75-83

1

1034 [Radiotherapy and targeted therapies in non-small-cell lung cancer]. **2009**, 96, 311-9

0

1033 MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. **2009**, 2009, 305908

25

1032 Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. **2009**, 2009, 849051

29

1031	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. 2009 , 2009, 567486		85
1030	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. 2009 , 2, 209-17		12
1029	Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. 2009 , 4, 27-33		7
1028	The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. 2009 , 16, 27-48		19
1027	Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. 2009 , 4, 988-93		3
1026	V15-32 and INTEREST. 2009 , 49, 944-949		
1025	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. 2009 , 1, CMT.S2122		
1024	Small-molecule inhibitors of the human epidermal receptor family. 2009 , 18, 1829-42		23
1023	Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. 2009 , 296, C954-76		122
1022	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1394-400	2.2	398
1021	Micropapillary histology: a frequent morphology of mutation-associated lung adenocarcinoma?. 2009 , 131, 615-7		6
1020	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. <i>Clinical Cancer Research</i> , 2009 , 15, 5267-73	12.9	328
1019	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. 2009 , 106, 16996-7001		218
1018	A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. 2009 , 17, 206-18		78
1017	Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation. 2009 , 69, 976-83		30
1016	Targeted therapy: comprehensive review. 2009 , 26, 137-46		5
1015	SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. 2009 , 37, W406-12		52
1014	Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. 2009 , 1, 137-44		17

1013	Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. 2009 , 20, 1813-7		41
1012	Current treatments for advanced stage non-small cell lung cancer. 2009 , 6, 233-41		113
1011	Randomized phase II study of gefitinib compared with placebo in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2253-60	2.2	106
1010	Lung cancer in women: the differences in epidemiology, biology and treatment outcomes. 2009 , 3, 627-34		15
1009	Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. 2009 , 20, 1455-1457		3
1008	Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. 2009 , 69, 873-8		135
1007	Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. <i>Clinical Cancer Research</i> , 2009 , 15, 907-13	12.9	44
1006	Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 5040-8	12.9	22
1005	Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. 2009 , 9, 663-70		25
1004	Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. 2009 , 76, 239-46		15
1003	Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?. 2009 , 77 Suppl 1, 113-21		73
1002	Adjuvant therapy for resected non-small cell lung cancer. 2009 , 1, 109-18		6
1001	Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. 2009 , 8, 206-12		9
1000	EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. 2009 , 4, 1466-72		59
999	Targeted therapies in lung cancer. 2009 , 15, 188-206		33
998	Targeting ERBB receptors to inhibit metastasis: old hopes and new certainties. 2009 , 9, 1-18		5
997	Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. 2009 , 3, 139-51		4
996	New Agents [Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing. 2009 , 5, 1-19		

995	I am no one. No one is perfect...Therefore I am perfect. <i>Journal of Clinical Oncology</i> , 2009 , 27, e128-9; author reply e130-1	2.2	1
994	Anti-apoptotic mechanisms of drug resistance in cancer. 2009 , 9, 307-19		132
993	Role of tyrosine kinase inhibitors in lung cancer. 2009 , 9, 569-75		24
992	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. 2009 , 6, 287-94		19
991	A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization. 2009 , 48, 471-3		1
990	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. 2009 , 4, e4576		154
989	First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. 2009 , 9, 425-35		23
988	Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). 2009 , 20, 835-41		56
987	EGFR-targeted therapies in lung cancer: predictors of response and toxicity. 2009 , 10, 59-68		54
986	The role of EGFR inhibition in the treatment of non-small cell lung cancer. 2009 , 14, 1116-30		44
985	Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4481-6	2.2	198
984	A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 2552-8	12.9	230
983	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 7502-7509	12.9	115
982	Bridging Study versus Prespecified Regions Nested in Global Trials. 2009 , 43, 27-34		5
981	Lung cancer in never smokers: molecular profiles and therapeutic implications. <i>Clinical Cancer Research</i> , 2009 , 15, 5646-61	12.9	122
980	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5650-9	2.2	103
979	EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. 2009 , 131, 478-89		64
978	Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. 2009 , 18, 133-7		9

977	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. 2009 , 20, 213-26		31
976	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naïve non-small-cell lung cancer. 2009 , 20, 696-702		161
975	Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1864-71	2.2	303
974	Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. <i>Clinical Cancer Research</i> , 2009 , 15, 4493-8	12.9	159
973	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. 2009 , 33, 1485-97		114
972	Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. 2009 , 2, 157		14
971	Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. 2009 , 10, 20-7		16
970	Second-line therapy for non-small-cell lung cancer. 2009 , 10, 91-8		5
969	S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. 2009 , 10, 290-4		24
968	Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. 2009 , 315, 2658-72		23
967	Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients. 2009 , 195, 179-82		10
966	The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. 2009 , 36, S55-68		8
965	Lung cancer outcomes in women. 2009 , 36, 532-41		13
964	EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. 2009 , 31, 1068-77		22
963	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. 2009 , 125, 2479-82		83
962	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. 2009 , 115, 1518-30		18
961	EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. 2009 , 117, 67-72		100
960	Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. 2009 , 135, 117-23		6

959	Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. 2009 , 135, 723-30	41
958	Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy. 2009 , 14, 125-9	1
957	Effect of gefitinib on warfarin antithrombotic activity. 2009 , 14, 332-6	12
956	Improvements of quality of life in patients with advanced non-small cell lung cancer treated with gefitinib. 2009 , 8, 495-497	2
955	Gefitinib is effective for pathological fracture of metastatic non-small cell lung cancer. 2009 , 19, 181-185	
954	Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. 2009 , 27, 1-11	7
953	Prolonged response to gefitinib in bone metastasis. 2009 , 26, 101-2	4
952	A population-based study of gefitinib in patients with non-small cell lung cancer. 2009 , 26, 222-7	8
951	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. 2009 , 3, 137-148	1
950	Histoculture drug response assay for gefitinib in non-small-cell lung cancer. 2009 , 57, 138-43	13
949	Investigational agents in the management of non-small cell lung cancer. 2009 , 11, 275-84	4
948	Maximum tolerated dose: clinical endpoint for a bygone era?. 2009 , 4, 143-7	38
947	The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. 2009 , 4, 235-52	46
946	Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom. 2009 , 2, 80-85	
945	A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression. 2009 , 21, 1-12	2
944	Molecular markers and pathogenically targeted therapy in non-small cell lung cancer. 2009 , 3, 245-255	1
943	Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma. 2009 , 15, 225-9	17
942	Radiosensitizing effects of gefitinib at different administration times in vitro. 2009 , 100, 1520-5	34

941	Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. 2009 , 100, 1931-4	13
940	Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. 2009 , 100, 2054-9	75
939	P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. 2009 , 16, 498-507	18
938	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. 2009 , 6, 352-66	178
937	The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. 2009 , 28 Suppl 1, S1-3	5
936	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. 2009 , 28 Suppl 1, S14-23	163
935	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. 2009 , 28 Suppl 1, S24-31	636
934	Gefitinib-induced autologous antitumor immunity. 2009 , 5, 119-122	
933	Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. 2009 , 103, 1729-37	20
932	Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. 2009 , 69, 223-36	7
931	Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. 2009 , 33, 73-111	17
930	Epidermal growth factor receptor inhibitors: current status and future directions. 2009 , 33, 245-94	9
929	Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. 2009 , 74, 1391-6	56
928	Cell Adhesion Molecules. 2009 , 19-28	
927	Current Clinical Management of Metastatic Lung Cancer. 2009 , 317-350	
926	Gefitinib - a potential new treatment option in lung cancer. 2009 , 10, 7-13	
925	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. <i>Clinical Cancer Research</i> , 2009 , 15, 2076-84	12.9 330
924	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2523-9	2.2 189

923	Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 264-70 ^{2,2}	49
922	Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. 2009 , 278, 17-26	22
921	Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. 2009 , 279, 213-20	13
920	Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. 2009 , 15, 326-35	24
919	Activated Akt prevents antitumor activity of gefitinib in renal cancer cells. 2009 , 74, 209-15	11
918	[New drugs in oncology and skin toxicity]. 2009 , 30, 401-10	12
917	Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. 2009 , 154, 9-12	9
916	The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. 2009 , 40, 356-65	34
915	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2653-9 ^{2,2}	237
914	Treatment of non-small cell lung cancer patients with performance status2 (PS2). 2009 , 63, 10-5	8
913	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. 2009 , 63, 219-26	177
912	Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. 2009 , 63, 418-24	41
911	EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology. 2009 , 64, 179-86	26
910	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. 2009 , 64, 199-206	19
909	Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. 2009 , 64, 341-5	7
908	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. 2009 , 64, 346-51	40
907	Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma. 2009 , 65, 204-7	24
906	Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. 2009 , 66, 114-9	53

905	Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor?. 2009 , 66, 262-7	64
904	Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. 2009 , 20, 70-1	4
903	Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer. 2009 , 23, 392-397	2
902	Next generation oncology drug development: opportunities and challenges. 2009 , 6, 259-65	57
901	Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. 2009 , 69, 2303-28	39
900	Cancer treatments: can we find treasures at the bottom of the sea?. 2009 , 10, 295-300	21
899	Recent advances of novel targeted therapy in non-small cell lung cancer. 2009 , 2, 2	52
898	Gefitinib for the treatment of non-small-cell lung cancer. 2009 , 9, 17-35	35
897	Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. 2009 , 20, 1483-1488	22
896	EGFR-directed therapies to treat non-small-cell lung cancer. 2009 , 18, 1133-45	8
895	Basic Concepts of Molecular Pathology. 2009 ,	1
894	Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. 2009 , 48, 578-83	109
893	Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. 2009 , 18, 293-301	13
892	The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. 2009 , 28, 123	15
891	Are we HER-ting for innovation in neoadjuvant breast cancer trial design?. 2009 , 11, 201	8
890	Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 2009 , 11, 1084-92	76
889	Chemotherapy for lung cancer: the state of the art in 2009. 2009 , 9, 1365-78	36
888	Is there a need to take ethnicity into account when considering lung cancer treatment?. 2009 , 3, 1-4	

887	Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. 2009 , 9, 1815-36		31
886	Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. 2009 , 16, 565-72		35
885	Ethnic differences in drug metabolism and toxicity from chemotherapy. 2009 , 5, 243-57		89
884	The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. 2009 , 14, 253-63		591
883	Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6229-36	2.2	77
882	Management of Rash and Other Toxicities in Patients Treated with Epidermal Growth Factor Receptor Targeted Agents. 2009 , 8, 3-8		
881	Gastrointestinal toxicities of novel agents in cancer therapy. 2009 , 45 Suppl 1, 332-42		23
880	Gefitinib in the treatment of advanced non-small-cell lung cancer. 2009 , 9, 401-12		17
879	Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. 2009 , 7, 4415-27		36
878	EGFR signaling and drug discovery. 2009 , 77, 400-10		324
877	Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment. 2009 , 29, 1-13		28
876	An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. 2009 , 32, 338-41		39
875	The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care?. 2009 , 15, 321-6		10
874	Treatment of Advanced Lung Cancer. 2009 , 16, 157-171		2
873	Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells. 2009 , 20, 832-7		14
872	Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. 2009 , 15, 401-5		59
871	Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. 2009 , 4, 684-8		59
870	Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. 2009 , 24, 473-9		2

869	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. 2009 , 4, 809-15	127
868	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. 2009 , 36,	0
867	Medical management of brain metastases from lung cancer (Review). 2009 , 22, 1269-76	42
866	Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. 2009 , 4, 1524-9	70
865	Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. 2009 , 4, 1136-43	23
864	Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. 2009 , 4, 994-1001	38
863	Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. 2009 , 4, 1415-9	129
862	NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. 2009 , 7 Suppl 1, S5-21; quiz S22-4	87
861	IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. 2009 , 4, 1126-35	43
860	Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?. 2009 , 15, 354-60	13
859	Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. 2009 , 15, 758-76	51
858	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. 2009 , 20, 856-66	43
857	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. 2010 , 21, 151-68	9
856	Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. 2010 , 5, 166-77	7
855	Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. 2010 , 16, 70-5	50
854	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. 2010 , 7, 121-124	2
853	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 2010 , 5, 1706-13	237
852	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. 2010 , 11, 851-64	40

851	Gender, histology, and time of diagnosis are important factors for prognosis: analysis of 1499 never-smokers with advanced non-small cell lung cancer in Japan. 2010 , 5, 1011-7	61
850	Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. 2010 , 5, 1197-200	62
849	Molecular Diagnostics Testing for Lung Adenocarcinoma. 2010 , 15, 103-110	1
848	Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. 2010 , 33, 66-9	8
847	Immunohistology--past, present, and future. 2010 , 17, 404-18	38
846	First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. 2010 , 5, 361-8	25
845	Recent development of molecular-targeted drugs in lung cancer. 2010 , 49, 1923-34	6
844	1. Basic and Clinical Practice of Molecular Target Therapy for Lung Cancers.. 2010 , 99, 2035-2051	
843	Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. 2010 , 5, 1404-9	42
842	Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. 2010 , 5, 491-6	35
841	Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?. 2010 , 5, 1495-7	2
840	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. 2010 , 5, 1424-9	26
839	Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. 2010 , 5, 169-78	60
838	Prognostic value of epidermal growth factor receptor expression in operable non-small cell lung carcinoma. 2010 , 5, 305-11	7
837	Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. 2010 , 23,	6
836	Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer. 2010 , 5, 1939-48	24
835	Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 2010 , 5, 1382-90	110
834	Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. 2010 , 49, 103-7	26

833	Japanese lung cancer research trends and performance in Science Citation Index. 2010 , 49, 2219-28	99
832	Personalizing therapy for ovarian cancer. 2010 , 7, 229-239	1
831	Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. 2010 , 5, 1175-84	42
830	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. 2010 , 65, 353-61	143
829	Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. 2010 , 65, 1023-8	24
828	Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer. 2010 , 66, 691-8	32
827	Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. 2010 , 65, 803-6	30
826	[Molecular diagnostics in lung carcinoma for therapy stratification]. 2010 , 31, 22-8	3
825	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. 2010 , 136, 527-35	11
824	Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. 2010 , 136, 1341-7	60
823	Impact of biomarkers on non-small cell lung cancer treatment. 2010 , 5, 5-17	14
822	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. 2010 , 5, 245-55	50
821	Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. 2010 , 27, 950-7	9
820	Biology and therapy of neoplastic meningitis. 2010 , 12, 41-9	24
819	A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China. 2010 , 22, 1-9	1
818	EGFR mutations and the terminal respiratory unit. 2010 , 29, 23-36	89
817	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. 2010 , 29, 49-60	164
816	Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. 2010 , 28, 791-9	59

815	Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study. 2010 , 19, e144-9	10
814	Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. 2010 , 11, 51-6	24
813	Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. 2010 , 11, 257-63	7
812	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. 2010 , 10, 376	48
811	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. 2010 , 15, 88-97	57
810	Molecular imaging and targeted therapies. 2010 , 80, 731-8	34
809	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. 2010 , 80, 613-23	69
808	Modeling NSCLC progression: recent advances and opportunities available. 2013 , 15, 542-50	11
807	Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib. 2013 , 72, 341-8	1
806	Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation. 2013 , 71, 705-11	6
805	Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. 2013 , 2, 22	5
804	Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. 2013 , 14, 680-7	15
803	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. 2013 , 39, 839-50	84
802	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 2013 , 8, 1381-97	6
801	Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. 2013 , 6, ra84	75
800	Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. 2013 , 14, 609-26	14
799	Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. 2013 , 4, 17	26
798	Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells. 2013 , 31, 525-34	9

797	Treatment outcomes in elderly with advanced-stage non-small cell lung cancer. 2013 , 191, 645-54	6
796	Epidermal growth factor receptor: pathway, therapies, and pipeline. 2013 , 35, 1282-303	66
795	Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1061-9	2.2 75
794	Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. 2013 , 49, 1216-25	79
793	Impact of genetic markers on treatment of non-small cell lung cancer. 2013 , 779, 145-64	6
792	Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. 2013 , 79, 8-13	79
791	Epidermal growth factor receptor exon 20 mutation increased in post-chemotherapy patients with non-small cell lung cancer detected with patients' blood samples. 2013 , 6, 504-10	6
790	The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. 2013 , 14, 311-21	10
789	Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. 2013 , 14, 502-7	40
788	Salivary gland cancer stem cells. 2013 , 49, 845-853	40
787	Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer. 2013 , 80, 319-25	11
786	Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer. 2013 , 76, 249-57	23
785	Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. 2013 , 69, 708-720	71
784	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. 2013 , 81, 435-439	28
783	Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. 2013 , 81, 280-7	39
782	Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib. 2013 , 517, 60-4	20
781	Epidemiology and Outcomes of Regimen-Related Toxicities. 2013 , 3-17	
780	Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. 2013 , 71, 1325-34	22

779	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). 2013 , 39, 252-60	57
778	Sex differences in the drug therapy for oncologic diseases. 2012 , 411-42	48
777	Chemotherapy and Biological Agents. 2013 , 49-64	
776	Cancer Chemotherapy. 2013 , 541-567	5
775	Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations. 2013 , 32, 2346-55, 2355.e1-10	32
774	Kinase inhibitors of marine origin. 2013 , 113, 6761-815	87
773	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. 2013 , 39, 489-97	25
772	Incorporating Pharmacogenomics in Drug Development. 2013 , 343-366	
771	EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. 2013 , 15, 396-404	23
770	Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. 2013 , 14, 14-8	26
769	Prognostic factors for patients with solitary bone metastasis. 2013 , 18, 164-9	7
768	Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment. <i>Journal of Clinical Oncology</i> , 2013 , 31, e6-8	2.2 5
767	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. 2013 , 19, 818-832	23
766	Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. 2013 , 15, 630-8	24
765	Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. 2013 , 9, 327-45	8
764	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. 2013 , 12, 7	10
763	Lung cancer in women: differences in epidemiology, biology, histology, and treatment outcomes. 2013 , 34, 792-801	29
762	Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)I]-morpholino-IPQA. 2013 , 2013, 549359	6

761	Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. 2013 , 21, 326-36		27
760	Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. 2013 , 50, 87-93		17
759	Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. 2013 , 3, 29-35		1
758	Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. 2013 , 35, 562-87		63
757	Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?. 2013 , 36, 57-63		23
756	A comparison of methods for EGFR mutation testing in non-small cell lung cancer. 2013 , 22, 190-5		22
755	Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report. 2013 , 24, 731-5		5
754	Personalized Treatment of Lung Adenocarcinoma. 2013 , 20, 309-314		
753	Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer. 2013 , 19, 263-71		4
752	Second-Line Therapy for Advanced NSCLC. 2013 , 18, 947-53		30
751	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3320-6	2.2	227
750	Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?. 2013 , 5, 249-70		34
749	Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 925-36	6.1	57
748	USP8 is a novel target for overcoming gefitinib resistance in lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3894-904	12.9	87
747	Stratified medicine: drugs meet genetics. 2013 , 22, 53-7		12
746	The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients. 2013 , 36, 110-5		26
745	Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. 2013 , 2013, 964743		16
744	Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. 2013 , 8, 204-8		20

743	SCUBE3 overexpression predicts poor prognosis in non-small cell lung cancer. 2013 ,	0
742	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model. 2013 , 104, 1440-6	24
741	EGFR and KRAS mutation analyses from specimens obtained by bronchoscopy and EBUS-TBNA. 2013 , 4, 264-272	4
740	Subtyping of pulmonary adenocarcinoma in cytologic specimens: the next challenge. 2013 , 121, 601-4	5
739	Union for International Cancer Control International Session: healthcare economics: the significance of the UN Summit non-communicable diseases political declaration in Asia. 2013 , 104, 773-8	5
738	Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study. 2013 , 4, 109-116	5
737	Classification and regression tree analysis of patients with non-small-cell lung cancer treated with gefitinib after chemotherapy. 2013 , 4, 280-286	1
736	Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene. 2013 , 30, 1463-72	5
735	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. 2013 , 2, 75-85	
734	Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. 2013 , 8, 1069-74	88
733	Gefitinib: re-emerging from the shadows. 2013 , 2, 423-437	
732	Identification of stage I non-small cell lung cancer patients at high risk for local recurrence following sublobar resection. 2013 , 143, 1365-1377	22
731	Epidermal growth factor receptor inhibition in lung cancer: status 2012. 2013 , 8, 373-84	99
730	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. 2013 , 11, 161-9	50
729	Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy. 2013 , 4, 736-54	65
728	The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. 2013 , 54, 1-14	16
727	The different radiosensitivity when combining erlotinib with radiation at different administration schedules might be related to activity variations in c-MET-PI3K-AKT signal transduction. 2013 , 6, 603-8	8
726	A multiple cavity malignancy involving the renal capsule, pleura and meninges: A case report and review of the literature. 2013 , 6, 709-712	2

725	Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer. 2013 , 5, 435-439	11
724	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. 2013 , 8, e52093	82
723	Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. 2013 , 8, e56112	28
722	Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors. 2013 , 8, e56704	10
721	mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. 2013 , 8, e62104	25
720	The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors. 2013 , 8, e68966	23
719	Quantitative proteomic analysis of human lung tumor xenografts treated with the ectopic ATP synthase inhibitor citreoviridin. 2013 , 8, e70642	19
718	Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. 2013 , 8, e59183	23
717	Identification of candidate genes for lung cancer somatic mutation test kits. 2013 , 36, 455-64	13
716	Esophageal cancer. 526-531	
715	Tyrosine-kinase inhibitors in oncology. 872-883	
714	Lung cancer in women. 2013 , 106, 582-7	5
713	Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids. 2014 , 7, 353-63	7
712	In-depth analysis shows synergy between erlotinib and miR-34a. 2014 , 9, e89105	53
711	Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. 2014 , 9, e103305	78
710	Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer. 2014 , 7, 841-52	10
709	Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. 2014 , 8, 1037-46	9
708	Targeted treatment of mutated -expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics. 2014 , 5, 73-79	1

707	Phase II Clinical Trial of Gefitinib for the Treatment of Chemona... Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status. 2014 , 8, 121-8	2
706	Molecular Targeted Therapy in Lung Cancer. 2014 , 34, 37	1
705	The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro. 2014 , 45, 641-52	7
704	Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation. 2014 , 74, 939-46	10
703	Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. 2014 , 399, 879-88	6
702	Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. 2014 , 2, 9	12
701	Afatinib and lung cancer. 2014 , 14, 1391-406	9
700	First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. 2014 , 23, 92-105	32
699	Kinase Inhibitors in Cancer. 2014 ,	2
698	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. 2014 , 110, 55-62	282
697	Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma. 2014 , 35, 373-80	5
696	Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors. 2014 , 21, 329-36	54
695	The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials. 2014 , 51 Suppl 3, e86-91	1
694	Evaluation of immunohistochemistry using two different antibodies and procedures for primary lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangement. 2014 , 8, 2155-2159	4
693	Gefitinib-induced interstitial pneumonia: A case report and review of the literature. 2014 , 7, 855-859	5
692	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. 2014 , 4, 204	111
691	Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future. 2014 , 4, 233	11
690	A comparison of consistency of detecting BRAF gene mutations in peripheral blood and tumor tissue of nonsmall-cell lung cancer patients. 2014 , 10 Suppl, C150-4	2

689	Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. 2014 , 10, 931-8	18
688	The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. 2014 , 7, ra78	28
687	EGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies: Clinical Trial Review. 2014 , 406-420	
686	Visual DNA microarray for detection of epidermal growth factor receptor (EGFR) gene mutations. 2014 , 74, 693-9	6
685	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. 2014 , 15, 2693-708	18
684	Molecular alterations in non-small-cell lung cancer: perspective for targeted therapy and specimen management for the bronchoscopist. 2014 , 19, 1117-25	10
683	A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. 2014 , 799, 85-117	76
682	Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors. 2014 , 3, 61-9	5
681	Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas. 2014 , 141, 420-8	18
680	Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification. 2014 , 105, 1245-53	16
679	Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. 2014 , 44, 1083-98	3
678	Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. 2014 , 9, 2265-72	76
677	Erlotinib. 2014 , 201, 109-23	10
676	Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials. 2014 , 4, 244	49
675	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. 2014 , 7, 22	23
674	Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. 2014 , 9, 506-11	38
673	Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review. 2014 , 9, 1180-6	21
672	Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. 2014 , 83, 316-23	31

671	Targeting epidermal growth factor receptor in the management of lung cancer. 2014 , 41, 101-9	19
670	Extending survival of stage IV non-small cell lung cancer. 2014 , 41, 69-92	32
669	Radiation therapy as a backbone of treatment of locally advanced non-small cell lung cancer. 2014 , 41, 57-68	16
668	Application of Translational Science to Clinical Development. 2014 , 1-21	
667	Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells. 2014 , 21 Suppl 4, S555-63	20
666	Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment. 2014 , 83, 252-8	14
665	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. 2014 , 83, 231-9	78
664	Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer. 2014 , 31, 893	5
663	Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. 2014 , 22, 1417-28	27
662	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. 2014 , 32, 145-53	21
661	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. 2014 , 89, 300-13	56
660	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. 2014 , 232, 274-82	40
659	Targeted therapy-induced diarrhea: A review of the literature. 2014 , 90, 165-79	37
658	Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma. 2014 , 35, 256-68	9
657	Guide to Targeted Therapies: EGFR mutations in NSCLC. 2014 ,	
656	Carcinome bronchique non [petites cellules : quelle chimiothérapie de rattrapage ?. 2014 , 6, 442-452	
655	European perspective for effective cancer drug development. 2014 , 11, 492-8	36
654	In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor. 2014 , 23, 5074-5085	40

653	Update on systemic therapy of advanced non-small-cell lung cancer. 2014 , 14, 1189-203		19
652	Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. 2014 , 23, 1333-48		41
651	The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. 2014 , 31, 209		13
650	Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. 2014 , 31, 228		20
649	Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells. 2014 , 28, 728-35		24
648	EGFR inhibitors and autophagy in cancer treatment. 2014 , 35, 11701-9		26
647	Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. 2014 , 140, 1901-9		30
646	Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer. 2014 , 32, 946-54		10
645	Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. 2014 , 210, 155-60		4
644	Epidermal growth factor receptor mutations in lung adenocarcinoma. 2014 , 94, 129-37		149
643	Tilting the balance of dose modification for oral anticancer drugs?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1537-9	2.2	8
642	Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. 2014 , 50, 638-48		49
641	Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. 2014 , 52, 82-91		27
640	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. 2014 , 40, 990-1004		60
639	Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors. 2014 , 44, 685-92		6
638	Review of the current targeted therapies for non-small-cell lung cancer. 2014 , 5, 576-87		50
637	Epidermal growth factor receptor inhibitors: coming of age. 2014 , 21, 74-9		51
636	[Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report]. 2014 , 69, 163-8		2

635	Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression. 2014 , 37, 355-60	3
634	SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. 2014 , 32, 2612-8	8
633	Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. 2014 , 32, 1401-8	6
632	A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinoma cancer without indication for chemotherapy. 2014 , 8, 1563-1566	4
631	Autophagy induction by low-dose cisplatin: the role of p53 in autophagy. 2014 , 31, 248-54	20
630	Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR. 2014 , 31, 2619-24	10
629	Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. 2014 , 9, 2417-22	12
628	Molecular Profiling. 2014 , 48-66	
627	Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations. 2014 , 21, 67-73	12
626	AG1478 inhibits the migration and invasion of cisplatin-resistant human lung adenocarcinoma cells via the cell cycle regulation by matrix metalloproteinase-9. 2014 , 8, 921-927	6
625	Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan. 2015 , 94, e969	29
624	MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells. 2015 , 11, 333-40	18
623	Is there a specific phenotype associated with the different subtypes of KRAS mutations in patients with advanced non-small-cell lung cancers?. 2015 , 90, 561-7	5
622	Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2015 , 94, e775	51
621	Implementation of modern therapy approaches and research for non-small cell lung cancer in Japan. 2015 , 20, 199-208	3
620	Targeted Therapy in Solid Tumors: Lung Cancer. 2015 , 224-230	
619	Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis. 2015 , 3, 403-407	9
618	The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations. 2015 , 5, 12675	11

617	Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment. 2015 , 5, 10648	7
616	Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. 2015 , 14, 83-93	10
615	Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. 2015 , 9, 2419-2421	2
614	Sulforaphane attenuates EGFR signaling in NSCLC cells. 2015 , 22, 38	25
613	Multiple primary malignancies involving lung cancer. 2015 , 15, 696	32
612	Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan. 2015 , 10, 127	10
611	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. 2015 , 22, 193-9	14
610	Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis. 2015 , 40, 661-71	9
609	FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients. 2015 , 40, 950-8	32
608	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. 2015 , 12, 187-91	12
607	Role of network biology and network medicine in early detection of cancer. 457-463	
606	Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. 2015 , 8, 3665-78	38
605	Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?. 2015 , 114, 530-6	16
604	Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region. 2015 , 3, 1371-1374	17
603	Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. 2015 , 41, 365-75	19
602	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line. 2015 , 8, 1603-10	9
601	Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. 2015 , 6, 5465-74	78
600	. 2015 ,	2

599 Gefitinib and Sonidegib. **2015**, 50, 868-872

598 Squamous non-small cell lung cancer as a distinct clinical entity. **2015**, 38, 220-6 23

597 Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. **2015**, 20, 12-28 78

596 EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 2221-6 12.9 59

595 Targeting EGFR in lung cancer: Lessons learned and future perspectives. **2015**, 45, 67-73 34

594 Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. **2015**, 11, 2175-91 4

593 Experience with erlotinib in the treatment of non-small cell lung cancer. **2015**, 9, 146-63 19

592 Comparison of droplet digital PCR and conventional quantitative PCR for measuring gene mutation. **2015**, 9, 1383-1388 57

591 Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA). **2015**, 153, 380-90 124

590 Are predictions of cancer response to targeted drugs, based on effects in unrelated tissues, the 'Black Swan' events?. **2015**, 11, 2307-14 2

589 Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. **2015**, 38, 560-9 5

588 Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. **2015**, 10, 153-70 35

587 Germline oncoparmacogenetics, a promising field in cancer therapy. **2015**, 38, 65-89 7

586 CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab. **2015**, 19, 79-89 7

585 Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights. **2015**, 1, 31-7 45

584 Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. **2015**, 76, 251-6 11

583 Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System. **2015**, 8, 519-534 3

582 Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review. **2015**, 22, e183-215 50

581	A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. 2015 , 51, 1904-10	14
580	Emerging treatment for advanced lung cancer with EGFR mutation. 2015 , 20, 597-612	17
579	CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines. 2015 , 87, 265-71	29
578	Association Between Parkinson Disease and Risk of Cancer in Taiwan. 2015 , 1, 633-40	48
577	Limitations in the Use of Serum Epidermal Growth Factor Receptor Mutations as Prognostic Markers for Non-Small-Cell Lung Cancer. 2015 , 24, 486-90	1
576	Clinical significance of gefitinib antitumor activity in patients with lung adenocarcinoma. 2015 , 9, 257-261	
575	Management of egfr tki-induced dermatologic adverse events. 2015 , 22, 123-32	50
574	Characterization of interaction of calf thymus DNA with gefitinib: spectroscopic methods and molecular docking. 2015 , 147, 47-55	74
573	Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. 2015 , 20, 400-10	89
572	Boron-Based Drug Design. 2015 , 15, 616-35	89
571	Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. 2015 , 136, 491-7	40
570	Advances in the Chemopreventive Targeting of Oral Carcinogenesis. 2015 , 2, 63-72	3
569	Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. 2015 , 89, 175-86	18
568	Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response. 2015 , 13, 111	4
567	The epidermal growth factor receptor (EGRF) in lung cancer. 2015 , 3, 1	26
566	Incidence and risk of xerosis with targeted anticancer therapies. 2015 , 72, 656-67	30
565	Histologic Classification and Its Need for Treatment of Lung Cancer. 2015 , 1-14	
564	Pattern recognition of HER-1 in biological fluids using stochastic sensing. 2015 , 30, 283-5	6

563	Racial differences in lung cancer genetics. 2015 , 10, 230-1	4
562	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer. 2015 , 45, 356-61	3
561	Management of EGFR mutated nonsmall cell lung carcinoma patients. 2015 , 45, 1132-41	25
560	A Novel and Efficient Synthesis of Anti-Cancer Agent, Mereletinib. 2015 , 39, 318-320	4
559	Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction. 2015 , 76, 713-21	1
558	Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. 2015 , 42 Suppl 2, S19-28	16
557	Considerations on the management of EGF receptor-TKIs for brain metastases in EGFR-mutant lung carcinoma patients. 2015 , 4, 43-49	1
556	Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer. 2015 , 27, 30-9	21
555	Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid. 2016 , 38, 410-6	8
554	Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer. 2016 , 129, 332-40	17
553	Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. 2016 , 7, 73618-73637	43
552	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. 2016 , 79, 248-256	27
551	IN SILICO IDENTIFICATION OF NOVEL EGFR TYROSINE KINASE INHIBITORS ASSOCIATED WITH NON-SMALL CELL LUNG CANCER FROM PHYTOCHEMICAL LIBRARY. 2016 , 7, 22-25	
550	A Hybrid Medical Image Compression Techniques for Lung Cancer. 2016 , 9,	0
549	Virtual screening of natural compounds as inhibitors of EGFR 696-1022 T790M associated with non-small cell lung cancer. 2016 , 12, 311-317	8
548	Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients. 2016 , 9, 1291-302	7
547	Evaluation of Scoring Systems and Prognostic Factors in Patients With Spinal Metastases From Lung Cancer. 2016 , 41, 638-44	17
546	Kinases inhibitors in lung cancer: From benchside to bedside. 2016 , 1866, 128-40	25

545	Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data. 2016 , 99, 69-75		19
544	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. 2016 , 138, 2549-61		119
543	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. 2016 , 38, 1567-76		7
542	Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer. 2016 , 30, 1150-1154		28
541	HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib. 2016 , 12, 5363-5369		2
540	Relationship between miR-7 expression and treatment outcomes with gefitinib in non-small cell lung cancer. 2016 , 12, 4613-4617		6
539	Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function. 2016 , 36, 3251-3258		13
538	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns. 2016 , 2, 223-230		23
537	Rationale of an economically driven PD1 biomarker development in lung cancer--An academic dilemma. 2016 , 9, 109-110		1
536	Traitement de seconde ligne et au-delà des cancers bronchopulmonaires non à petites cellules de stade IV en l'absence d'addiction oncogénique. 2016 , 8, 361-372		
535	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. 2016 , 21, 962-76		35
534	Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3248-57	2.2	102
533	Integrin $\alpha 1$ -mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. 2016 , 11, 535-542		16
532	Hepatotoxicity of targeted therapy for cancer. 2016 , 12, 789-802		10
531	Strategies to overcome acquired resistances conferred by mutations in the kinase domain of EGFR. 2016 , 8, 853-78		14
530	Safety of gefitinib in non-small cell lung cancer treatment. 2016 , 15, 993-1000		5
529	Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?. <i>Clinical Cancer Research</i> , 2016 , 22, 2127-32	12.9	14
528	Exploration of optimal time for initiating adjuvant chemotherapy after surgical resection: A retrospective study in Chinese patients with stage IIIA non-small cell lung cancer in a single center. 2016 , 7, 399-405		2

527	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. 2016 , 388, 1002-11	113
526	Resistance to Therapy. 2016 , 170, 183-202	6
525	Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma. 2016 , 94, 20-2	5
524	Overexpression of CD44 is associated with the occurrence and migration of non-small cell lung cancer. 2016 , 14, 3159-67	22
523	Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro. 2016 , 194, 1043-1050	19
522	Gefitinib as first line therapy in Malaysian patients with mutation-positive non-small-cell lung cancer: A single-center retrospective study. 2016 , 11, 2757-2762	1
521	Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry. 2016 , 14, 4823-4829	3
520	Evaluation of the potential synergism of imatinib-related poly kinase inhibitors using growth factor stimulated proteoglycan synthesis as a model response. 2016 , 68, 368-78	7
519	Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib. 2016 , 93, 20-7	2
518	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. 2016 , 11, 317-27	8
517	Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients. 2016 , 138, 1003-12	13
516	A Predictive Model for Personalized Therapeutic Interventions in Non-small Cell Lung Cancer. 2016 , 20, 424-31	25
515	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. 2016 , 20, 55-63	18
514	FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 1307-12	12.9 122
513	Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. 2016 , 7, 61-5	7
512	Skin problems and EGFR-tyrosine kinase inhibitor. 2016 , 46, 291-8	59
511	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. 2016 , 17, 18	14
510	Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer. 2016 , 27, 245-50	14

509	Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors. 2016 , 24, 1495-503	17
508	Recent advances in the pathology and molecular genetics of lung cancer: A practical review for cytopathologists. 2016 , 5, 252-265	
507	The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer. 2016 , 43, 3-10	4
506	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. 2016 , 11, 556-65	176
505	Gender, Sex Hormones and Respiratory Disease. 2016 ,	5
504	Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel. 2016 , 17, 855-63	17
503	Sex-Specific Differences in Lung Cancer. 2016 , 147-171	2
502	A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. 2016 , 18, 228-38	25
501	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. 2016 , 50, 164-76	28
500	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. 2016 , 22, 461-76	21
499	Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET. 2016 , 15, 234-42	15
498	A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. 2017 , 116, 568-574	120
497	Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer. 2017 , 21, 179-185	20
496	Strategies to design clinical studies to identify predictive biomarkers in cancer research. 2017 , 53, 79-97	64
495	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. 2017 , 174, 1-21	87
494	Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. 2017 , 13, 304-313	10
493	Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy-naïve patients with advanced or metastatic non-small-cell lung cancer: Long-term follow-up results. 2017 , 6, 56-62	1
492	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. 2017 , 6, 259-268	13

491	An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. 2017 , 8, 871-885	88
490	Leveraging Genomic Factors to Improve Benefit-Risk. 2017 , 10, 78-83	3
489	Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival. 2017 , 79, 1013-1020	9
488	Cancer of the Lung. 2017 , 1-30	0
487	F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Non-Small Cell Lung Cancer Patients: A Comparison of Assessment Methods. 2017 , 58, 1931-1937	8
486	Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm. 2017 , 31, 83-99	9
485	Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs. 2017 , 17, 143-155	19
484	Development and Evaluation of F-IRS for Molecular Imaging Mutant EGF Receptors in NSCLC. 2017 , 7, 3121	16
483	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. 2017 , 34, 121	11
482	Drug-biomarker co-development in oncology - 20 years and counting. 2017 , 30, 48-62	38
481	Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. 2017 , 25, 3148-3157	21
480	Dose determination for molecularly targeted therapies: Much Ado About Nothing. 2017 , 123, 1298-1300	1
479	Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors. 2017 , 65, 935-941	3
478	EGFR gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis. 2017 , 65, 72-81	12
477	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. 2017 , 20, 487-495	61
476	Gefitinib: an orphan drug for non-small cell lung cancer. 2017 , 5, 899-906	1
475	Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. 2017 , 40, 419-441	57
474	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. 2017 , 35, 1195-1209	14

473	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. 2017 , 34, 175	4
472	MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. 2017 , 39, 1010428317706430	12
471	Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas EGFR mutation test. 2017 , 111, 190-194	11
470	Evaluate the relative efficiency of a targeted clinical trial design to an untargeted design under the issue of cost. 2017 , 46, 12336-12344	1
469	Impact of metastatic status on the prognosis of mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. 2017 , 14, 7589-7596	14
468	Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis. 2017 , 14, 4017-4032	10
467	Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. 2017 , 79, 497-505	15
466	Adverse kidney effects of epidermal growth factor receptor inhibitors. 2017 , 32, 1089-1097	30
465	Capilliposide from <i>Lysimachia capillipes</i> inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. 2017 , 38, 100-109	10
464	Targeting Oncoproteins for Molecular Cancer Therapy. 2017 , 727-756	
463	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). 2017 , 45, 36-49	8
462	At the crossroads of cancer stem cells and targeted therapy resistance. 2017 , 385, 87-96	19
461	Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance. 2017 , 23, 307-315	11
460	Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECURSE trial. 2017 , 19, 227-235	18
459	Epidemiology of Lung Cancer. 2017 , 347-366	1
458	A novel ARMS-based assay for the quantification of mutations in patients with lung adenocarcinoma. 2018 , 15, 2905-2912	9
457	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. 2017 , 11, 787	24
456	Gefitinib. 2017 , 123-144	

455	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. 2017 , 9,	14
454	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. 2017 , 4, 39	17
453	Tyrosine kinase domain mutations of gene in head and neck squamous cell carcinoma. 2017 , 10, 1527-1533	9
452	Concepts, Characteristics, and Clinical Validation of IBM Watson for Oncology. 2017 , 37, 49	5
451	The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro. 2017 , 17, 545-555	16
450	Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity. 2017 , 56, 2895-2898	5
449	Selective Kinase Inhibitors in Cancer. 2017 , 39-75	3
448	The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. 2017 , 8, 33736-33744	13
447	A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. 2017 , 7, 23	217
446	Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. 2017 , 9, 470-473	0
445	[Hepatotoxicity of tyrosine kinase inhibitors: Mechanisms involved and practical implications]. 2018 , 105, 290-298	1
444	Prognostic factors for post-recurrence survival in patients with completely resected Stage III (N2) non-small-cell lung cancer. 2018 , 54, 554-559	4
443	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. 2018 , 36, 495-504	18
442	Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer. 2018 , 41, 18-27	14
441	Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years. 2018 , 29, i1-i2	2
440	Gefitinib for advanced non-small cell lung cancer. 2018 , 1, CD006847	28
439	The biology and management of non-small cell lung cancer. 2018 , 553, 446-454	1499
438	Have Clinical Trials Properly Assessed c-Met Inhibitors?. 2018 , 4, 94-97	24

437	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. 2018 , 126, 217-223	67
436	Personalized Lung Cancer Treatment: A Teamwork. 2018 , 333-348	1
435	Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP). 2018 , 124, 2407-2414	9
434	Petri net siphon analysis and graph theoretic measures for identifying combination therapies in cancer. 2018 , 15, 231-243	8
433	Gender-Related Differences in Lung Cancer. 2018 , 30-45.e5	
432	Systemic Options for Second-Line Therapy and Beyond. 2018 , 434-447.e5	
431	Genotyping of common EGFR mutations in lung cancer patients by electrochemical biosensor. 2018 , 150, 176-182	11
430	Orient Expression: Solving the Mystery of Asian Prostate Cancer?. 2018 , 73, 340-342	2
429	Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer. 2018 , 19, 105-114	16
428	Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial. 2018 , 24, 734-740	12
427	Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients. 2018 , 9, 151-155	8
426	Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance. 2018 , 7, S123-S126	1
425	Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors. 2018 , 11, 8885-8899	2
424	Role of Cytokines in Combinatorial Immunotherapeutics of Non-Small Cell Lung Cancer Through Systems Perspective. 2018 ,	
423	Affibody-mediated imaging of EGFR expression in prostate cancer using radiocobalt-labeled DOTA-ZEGFR:2377. 2019 , 41, 534-542	3
422	Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. 2018 , 2018, 6192187	21
421	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. 2018 , 10,	14
420	Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold. 2018 , 61, 11372-11383	15

419	Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer. 2018 , 9, 963	18
418	Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. 2018 , 10, 1758835918797589	26
417	EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP). 2018 , 13, 621-629	16
416	Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors. 2018 , 16, 462-478	5
415	Biopharmaceutical Applied Statistics Symposium. 2018 ,	
414	Molecular Diagnostics in Clinical Oncology. 2018 , 5, 76	64
413	Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells. 2018 , 38, 5165-5176	10
412	Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. 2018 , 11, 665-675	7
411	Translational Sepsis Research: Spanning the Divide. 2018 , 46, 1497-1505	7
410	Identification of circulating tumor cells with EML4-ALK translocation using fluorescence hybridization in advanced ALK-positive patients with lung cancer. 2018 , 15, 8959-8964	2
409	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. 2018 , 144, 1601-1611	6
408	Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. 2018 , 123, 60-69	35
407	Small Molecules in Oncology. 2018 ,	3
406	Erlotinib. 2018 , 211, 1-17	12
405	Gefitinib. 2018 , 211, 235-246	32
404	Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks. 2018 , 91, 20180334	12
403	Pharmacogenomics and Pharmacoeugenomics: Impact on Therapeutic Strategies. 2018 , 227-238	1
402	Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. 2018 , 8, 92	356

401	Erlotinib-Associated Rash in Advanced Non-Small Cell Lung Cancer: Relation to Clinicopathological Characteristics, Treatment Response, and Survival. 2018 , 26, 59-69	5
400	Erlotinib as adjuvant therapy in EGFR-mutant NSCLC. 2018 , 6, 808-810	1
399	Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases. 2018 , 9, 1607-1613	4
398	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. 2018 , 4, 1207-1213	39
397	Clinical Proteomics and Molecular Pathology. 2018 , 183-203	
396	A Structural View on Medicinal Chemistry Strategies against Drug Resistance. 2019 , 58, 3300-3345	36
395	Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. 2019 , 131, 3336-3383	5
394	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. 2019 , 193, 20-30	35
393	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. 2019 , 8,	18
392	Correlation between adverse events after drug treatment and the C3435T polymorphism in advanced non-small cell lung cancer patients in an Asian population: a meta-analysis. 2019 , 47, 3522-3533	
391	Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization. 2019 , 17, 164-174	31
390	EGFR Targeted Therapy. 2019 , 1-30	0
389	A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. 2019 , 9, 12329	15
388	The Relevance of Gender in Tumor-Influencing Epigenetic Traits.. 2019 , 3,	3
387	Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo. 2019 , 382, 114734	12
386	Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. 2019 , 30, 1978-1984	40
385	Introduction. 2019 , 1-24	2
384	Incorporating Pharmacogenomics in Drug Development: A Perspective From Industry. 2019 , 81-101	

383	Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. 2019 , 12, 635-645	70
382	SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity. 2019 , 13, 1874-1886	13
381	Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective. 2019 , 8, 1976-1995	9
380	Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics. 2019 , 84, 51-60	10
379	Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. 2019 , 115-131	
378	Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. 2019 , 10, 880-889	8
377	Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. 2019 , 172, 364-371	11
376	Targeting exon 20 insertion mutations in non-small cell lung cancer. 2019 , 4, 5	129
375	High levels of EGFR prevent sulforaphane-induced reactive oxygen species-mediated apoptosis in non-small-cell lung cancer cells. 2019 , 64, 152926	7
374	Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. 2019 , 8,	15
373	Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. 2019 , 59, 3-22	12
372	Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling. 2019 , 29, 4742-4750	62
371	Erlotinib as standard adjuvant therapy for resectable mutation-positive non-small cell lung cancer. 2019 , 8, S369-S372	3
370	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. 2019 , 25, 245-253	3
369	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. 2019 , 8, S235-S246	6
368	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. 2019 , 8, S265-S279	10
367	Comparison of quality of life of patients on treatment with cisplatin and gemcitabine, carboplatin and gemcitabine, carboplatin and paclitaxel, carboplatin and pemetrexed for non-small cell lung cancer. 2019 , 25, 1853-1859	2
366	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. 2019 , 3, 385-408	11

365	Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors. 2019 , 10, 22-26	7
364	Resistance to molecularly targeted therapy in non-small-cell lung cancer. 2019 , 57, 20-26	32
363	Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. 2020 , 159, 1598-1610.e3	9
362	Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry. 2020 , 34, 369-379	2
361	Genomics and the History of Precision Oncology. 2020 , 29, 35-49	8
360	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. 2020 , 111, 4480-4489	13
359	Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. 2020 , 15, e0238120	3
358	EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges. 2021 , 107, 376-384	0
357	An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. 2020 , 147, 2621-2633	3
356	Platinum(II) Terpyridine Anticancer Complexes Possessing Multiple Mode of DNA Interaction and EGFR Inhibiting Activity. 2020 , 8, 210	16
355	Genomics-guided pre-clinical development of cancer therapies.. 2020 , 1, 482-492	9
354	First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects. 2020 , 38, 1826-1835	1
353	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. 2020 , 9,	9
352	The top 100 cited articles in lung cancer - a bibliometric analysis. 2020 , 24, 17-28	3
351	Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters. 2020 , 45, 1159-1167	2
350	Applying bioethical principles for directing investment in precision medicine. 2020 , 15, 23-28	1
349	First-iGAP: A Randomized Placebo-Controlled Phase II Study of First-line Intercalated Gefitinib and Pemetrexed-Cisplatin Chemotherapy for Never-Smoker Lung Adenocarcinoma Patients. 2020 , 21, e572-e582	
348	Adverse cutaneous reactions to chemotherapeutic drugs. 2020 , 38, 712-728	4

347	Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity. 2020 , 85, 605-614	0
346	Epidermal Growth Factor Receptor Mutations. 2020 , 30, 127-136	8
345	Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in -Mutant Non-small Cell Lung Cancer. 2020 , 11, 281	18
344	Cutaneous Squamous Cell Carcinoma: From Biology to Therapy. 2020 , 21,	36
343	Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study. 2020 , 12, 639-650	4
342	Impact of Tyrosine Kinase Inhibitor Starting Dose on Outcomes in Patients With Non-Small Cell Lung Cancer. 2021 , 34, 11-16	1
341	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. 2021 , 14, 100951	3
340	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present). 2021 , 31, 223-238	5
339	LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis. 2021 , 20, 179-193	3
338	AIM in Genomic Basis of Medicine: Applications. 2021 , 1-10	
337	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook. 2021 , 13, e13470	2
336	High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. 2021 , 13, 1476-1484	1
335	Ocular Toxicity of Targeted Anticancer Agents. 2021 , 81, 771-823	5
334	Clinical cancer genomic profiling. 2021 , 22, 483-501	15
333	The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics. 2021 , 701, 108811	7
332	Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. 2021 , 11, 684073	2
331	Epidermal Growth Factor Receptor Mutation Mechanisms in Nonsmall Cell Lung Cancer by Transcriptome Sequencing. 2021 ,	0
330	The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer. 2021 , 147, 2239-2248	

329	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. 2021 , 10,	4
328	Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma. 2021 , 12, 605797	0
327	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. 2021 , 13,	9
326	Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: Gefitinib and afatinib. 2021 , 343, 1-10	6
325	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. 2021 , 2, 207-222	
324	Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: A prospective, multicenter, dose-modification study. 2021 , 21, 881-886	1
323	Targeting Akt in cancer for precision therapy. 2021 , 14, 128	12
322	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. 2021 , 112, 5000-5010	1
321	The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. 2021 , 110, 3507-3519	1
320	Erlotinib for advanced non-small cell lung cancer.	1
319	Obstacles and opportunities in the clinical development of targeted therapeutics. 2005 , 63, 19-41	10
318	Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. 2005 , 63, 93-114	9
317	Targeting small molecules in cancer. 2007 , 135, 239-55	2
316	Update on the role of EGFR inhibitors in cancer therapeutics. 2007 , 135, 257-75	3
315	Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?. 2008 , 610, 128-43	4
314	Somatic Genetic Alterations and Implications for Targeted Therapies in Cancer (GIST, CML, Lung Cancer). 2010 , 205-220	1
313	Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) Receptors. 2008 , 147-160	1
312	Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients. 2019 , 1168, 79-90	2

311	Identifying critical signaling molecules for the treatment of cancer. 2007 , 172, 5-24	2
310	Erlotinib. 2010 , 184, 21-31	3
309	Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. 2006 , 24, 117	1
308	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. 2008 , 1307-1366	4
307	DEFINITIVE MANAGEMENT OF INOPERABLE NONSMALL CELL LUNG CANCER. 2008 , 804-821	1
306	Growth Factor Signaling Pathways and Receptor Tyrosine Kinase Inhibitors. 2006 , 155-172	2
305	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. 2012 , 58, 263-268	4
304	DNA-binding agents. 2005 , 163-203	5
303	Epidermal growth factor receptor pathway inhibitors. 2005 , 22, 205-23	11
302	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. 2006 , 1, 52-60	11
301	Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients. 2006 , 1, 417-424	17
300	Docetaxel in Combination with Either Cisplatin or Gemcitabine in Unresectable Non-small Cell Lung Carcinoma: A Randomized Phase II Study by the Japan Lung Cancer Cooperative Clinical Study Group. 2006 , 1, 447-453	19
299	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. 2006 , 1, 545-550	6
298	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. 2006 , 1, 582-587	10
297	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. 2006 , 1, 965-971	33
296	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. 2006 , 1, 1002-1009	111
295	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. 2007 , 2, 22-28	129
294	Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. 2007 , 18, 949-54	8

293	Oncogenes come of age. 2005 , 70, 1-9		21
292	Clinical trial design issues in the era of targeted therapies. <i>Clinical Cancer Research</i> , 2004 , 10, 4281s-4282s.	12.9	7
291	Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. <i>Clinical Cancer Research</i> , 2004 , 10, 4210s-4214s	12.9	47
290	Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. <i>Clinical Cancer Research</i> , 2004 , 10, 4205s-4209s	12.9	41
289	Personalized therapy for lung cancer: striking a moving target. 2018 , 3,		74
288	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. 2006 , 116, 2695-706		372
287	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. 2008 , 118, 2609-19		389
286	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. 2016 , 22, 276-83		12
285	Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung. 2007 , 74, 402-8		11
284	Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). 2013 , 13, 202-17		5
283	Tobacco Smoking and Lung Cancer: Perception-changing facts. 2013 , 13, 345-58		54
282	Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy. 2011 , 6, e23756		78
281	An anilinoquinazoline derivative inhibits tumor growth through interaction with hCAP-G2, a subunit of condensin II. 2012 , 7, e44889		11
280	Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. 2013 , 8, e59314		43
279	Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. 2014 , 9, e107276		19
278	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. 2015 , 20, 57-63		16
277	Development of rheumatoid arthritis during the course of gefitinib therapy. 2009 , 127, 177-8		2
276	Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress. 2016 , 7, 50043-50056		22

275	Risk of lung cancer in Parkinson's disease. 2016 , 7, 77319-77325	6
274	Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies. 2016 , 7, 86902-86913	11
273	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. 2017 , 8, 43555-43570	8
272	EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR. 2014 , 5, 1265-78	34
271	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. 2017 , 8, 100801-100818	28
270	Personalizing therapy with targeted agents in non-small cell lung cancer. 2011 , 2, 165-77	49
269	Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O-methylguanine-DNA methyltransferase with a double arm hybrid molecule. 2018 , 9, 35041-35055	3
268	The correlation of p22 and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma. 2019 , 10, 1119-1131	1
267	A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. 2015 , 6, 4527-36	68
266	Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. 2015 , 6, 814-24	12
265	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. 2015 , 6, 30929-38	9
264	The promise of anti-ErbB3 monoclonals as new cancer therapeutics. 2012 , 3, 744-58	70
263	KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. 2016 , 7, 8373-88	54
262	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. 2016 , 7, 40781-40791	6
261	The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors.. 2019 , 2, 326-334	1
260	EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.. 2019 , 8, S23-S47	19
259	Chemotherapy and molecular targeting therapy for recurrent cervical cancer. 2016 , 28, 241-53	26
258	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. 2019 , 19, 595-630	17

257	Achievements in Cancer Research and its Therapeutics in Hundred Years. 2019 , 19, 1545-1562	0
256	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. 2020 , 20, 815-834	64
255	Serum Levels of KL-6, SP-A and SP-D in NSCLC Patients Treated With Gefitinib. 2005 , 45, 823-828	2
254	A Case of Lung Adenocarcinoma with Gefitinib-resistant Carcinomatous Meningitis Exhibiting the Dose-dependent Effects of Erlotinib. 2014 , 54, 806-811	0
253	Two Cases of Stage IV Lung Adenocarcinoma That Achieved a Long-term Survival on Gefitinib. 2015 , 55, 1029-1036	0
252	[Successful treatment of non-small cell lung cancer by gefitinib in an elderly patient with poor performance status]. 2008 , 45, 338-42	2
251	Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. 2015 , 19, 1-134	8
250	[Relationship of epidermal growth factor receptor in lung development]. 2012 , 34, 27-32	3
249	Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. 2005 , 11, 1382-6	26
248	Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. 2006 , 12, 5140-7	21
247	[Advances on driver oncogenes of non-small cell lung cancer]. 2015 , 18, 42-7	3
246	EGFR and KRAS mutations in patients with adenocarcinoma of the lung. 2009 , 24, 48-54	56
245	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. 2010 , 2, 144-53	7
244	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). 2011 , 3, 57-64	15
243	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. 2013 , 5 Suppl 5, S579-92	29
242	Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. 2014 , 5, 57-66	4
241	Gefitinib in non-small-cell lung cancer-an old lesson new re-visited. 2013 , 2, 435-8	2
240	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. 2015 , 4, 36-54	389

239	A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia. 2017 , 54, 104-114	1
238	The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. 2013 , 19, 48-53	4
237	Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. 2016 , 7, 119-23	16
236	Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and Genes. 2018 , 13, 46-52	7
235	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. 2019 , 2, 36	2
234	The safety and efficacy of second-line single docetaxel (75 mg/m ²) therapy in advanced non-small cell lung cancer patients who were previously treated with platinum-based chemotherapy. 2005 , 37, 339-43	4
233	Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. 2012 , 44, 74-84	9
232	How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution. 2013 , 45, 178-85	11
231	Two-stage design for phase II oncology trials with relaxed futility stopping. 2016 , 9, 93-98	3
230	Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. 2006 , 4, 168-78	8
229	Lung cancer. 2005 , 25, 1-12	16
228	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. 2011 , 2, 367-76	31
227	Advances in adjuvant systemic therapy for non-small-cell lung cancer. 2014 , 5, 633-45	18
226	Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. 2014 , 5, 858-64	7
225	Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?. 2015 , 6, 45-56	3
224	Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. 2008 , 41, 626-34	23
223	Non-small cell lung cancer--genetic predictors. 2013 , 157, 125-36	30
222	EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis. 2011 , 30, 701-11	10

221	The evolution of phase I trials in cancer medicine: a critical review of the last decade. 2011 , 30, 815-20	2
220	Relationship between epidermal growth factor receptor gene mutation and copy number in Chinese patients with non-small cell lung cancer. 2012 , 31, 491-9	11
219	Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?. 2010 , 134, 66-72	70
218	Molecular diagnostics of lung carcinomas. 2011 , 135, 622-9	21
217	Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. 2011 , 135, 655-64	27
216	Tyrosine kinase - Role and significance in Cancer. 2004 , 1, 101-115	283
215	Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. 2015 , 16, 7071-6	5
214	Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area. 2016 , 17, 785-9	5
213	Acneiform Follicular Eruption in Patients Treated with Gefitinib: Report of Six Cases. 2004 , 66, 599-601	
212	Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines. 2004 , 16, 147-159	
211	Three Cases of Primary Non-Small Cell Lung Carcinoma with Mutation of the Epidermal Growth Factor Receptor Gene that Responded to Gefitinib. 2005 , 55, 169-176	
210	New Chemotherapeutic Agents. 2005 , 45, 793-799	
209	Lung cancer. 2005 , 22, 413-42	
208	Treatment Strategy for N2 Non-Small-Cell Lung Cancer:. 2005 , 45, 295-299	
207	Treatment of non-small cell lung cancer. 2005 , 65-125	
206	Lung Cancer. 2005 , 319-340	
205	Pitfalls in the Design, Conduct and Analysis of Randomized Clinical Trials. 2005 , 567-579	
204	Prediction of Sensitivity of Non-small Cell Lung Cancers to Gefitinib by Gene Expression Profiling. 2006 , 46, 245-251	

203 Nichtkleinzelliges Lungenkarzinom. **2006**, 3467-3584

202 Bronchioloalveoläres Karzinom und weitere seltene Lungentumoren. **2006**, 3626-3640

201 A Case of Adenocarcinoma of the Lung with a Favorable Response to Retreatment with Gefitinib. **2006**, 46, 357-362 3

200 Update Chemotherapy for Lung Cancer. **2006**, 52, 536-545

199 Gefitinib: impact on survival benefit. **2006**, 21, 58-63

198 Effect of Gefitinib on Quality of Life in Patients with Advanced Non-small-cell Lung Cancer in General Practice. **2006**, 32, 1033-1037 1

197 Multicenter Open-label Extension Trial of Long-term Treatment with Gefitinib (IRESSA®). **2006**, 46, 345-352

196 Retrospective Study of Alternate-day Administration of Gefitinib. **2007**, 47, 9-12 1

195 Re-treatment with Gefitinib for Non-small Cell Lung Cancer. **2007**, 47, 689-694 2

194 Malignome des Respirationstrakts. **2007**, 511-548

193 Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. **2007**, 2007, 144-146 0

192 High Density Tissue Microarray for Establishing Lung Cancer Expression Profiling Database and Its Clinical Application. **2007**, 47, 915-919

191 Epidermal Growth Factor Receptor Inhibition in NonSmall Cell Lung Cancer. **2007**, 81-96

190 Epidermal Growth Factor Receptor Targeted TherapyMarkers of Sensitivity and Response. **2007**, 97-122

189 Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. **2007**, 19-44

188 Therapeutic Targeting of Apoptosis in Cancer. **2008**, 263-278

187 Monoclonaux contre inhibiteurs de tyrosine kinase. **2008**, 81-97

186 Cell Adhesion Molecules. **2008**, 22-39

- 185 Response to Conventional Therapy and Targeted Molecular Therapy. **2008**, 226-232
- 184 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365
- 183 Phase 1 Trials Today. **2008**, 553-570
- 182 A Case of Adenocarcinoma of the Lung with Malignant Pleural Effusion and Elevated Serum IL-6 Levels Successfully Treated with Gefitinib. **2008**, 48, 273-278
- 181 Fundamentals of Cancer Cell Biology and Molecular Targeting. **2008**, 1933-1945
- 180 EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. **2008**, 281-324
- 179 Targeting Signaling Pathways in Cancer Therapy. **2009**, 309-326
- 178 EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. **2009**, 49, 409-415
- 177 Difference of EGFR-Binding Proteins between Wild Type and Mutant EGFR. **2009**, 132-138
- 176 Targeted Approaches to Drug Development. **2009**, 57-98
- 175 CELL CYCLE PHARMACOLOGY, ANTIPROLIFERATION, AND APOPTOSIS. **2009**, 83-90
- 174 The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy. **2009**, 191-219
- 173 Terminating Chemotherapy and Transition to Palliative Care for Patients with Recurrent Non-small Cell Lung Cancer in the Terminal Stage. **2009**, 49, 836-843
- 172 Selective Use of Gefitinib and Erlotinib on Non-small Cell Lung Cancer Patients. **2009**, 49, 950-956
- 171 Retrospective Analysis of Acquired Resistance During the Treatment with Gefitinib in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations. **2009**, 49, 257-261
- 170 Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients. **2009**, 43, 509
- 169 Palliative Chemotherapy and Corticosteroids. **2009**, 1360-1363
- 168 Clinical Analysis of 24 Cases Treated Twice or More with Gefitinib for Recurrent Non-small Cell Lung Cancer. **2009**, 49, 831-835

- 167 Individualization of treatment in non-small cell lung cancer. **2009**, 1, 1
- 166 A resected case of lung metastasis after treatment with gefitinib. **2010**, 24, 166-169
- 165 Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer. **2010**, 195-204
- 164 A Patient with Advanced Lung Adenocarcinoma Effectively Treated with Gemcitabine Plus Vinorelbine After Failure with Gefitinib. **2010**, 50, 297-302 1
- 163 Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. **2010**, 205-226 0
- 162 Effects of Antacids on Clinical Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer. **2010**, 36, 832-839 2
- 161 Quality of Life for Patients Receiving Cancer Chemotherapy: The Japanese Perspective. **2010**, 2923-2933
- 160 Pharmacodiagnostic Testing. **2010**, 87-117
- 159 Epidermal Growth Factor Receptor-Targeted Therapies. **2011**, 305-333
- 158 Targeted Therapeutics in Cancer Treatment. **2011**, 403-461
- 157 Translational Research in Lung Cancer. **2011**, 793-808
- 156 Lung Adenocarcinoma. **2011**, 177-183
- 155 Epidermal Growth Factor Receptor Inhibition as a Therapeutic Strategy for Glioblastoma Multiforme. **2011**, 321-336
- 154 Pharmacogenomics and Personalized Medicine. **2011**, 1359-1382
- 153 Erlotinib for advanced non-small cell lung cancer.
- 152 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61
- 151 Pharmacogenomics in Developing Asian Countries. **2012**, 183-214
- 150 Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominant Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report. **2012**, 4, 216-20 4

- 149 Efficacy and Safety of Gefitinib or Platinum plus Taxane in Egfr-Mutant Advanced Non-Small Cell Lung Cancers: A Meta-Analysis of First-Line Randomized Controlled Trials. **2012**, 03, 467-476
- 148 A case of primary lung cancer with EGFR mutation which needed to be distinguished from lung metastasis of breast cancer. **2012**, 51, 120-124
- 147 Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. **2012**, 2, 1-9
- 146 Treatment of non-small cell lung cancer in the era of targeted therapy. **2012**, 01, 1-4
- 145 Molecular Targeted Therapy of Lung Cancer. **2012**, 99-107
- 144 Principles of Chemotherapy. **2012**, 165-179
- 143 Clinical Analysis of 17 Cases Beginning Treatment with Erlotinib the Day After Terminating Gefitinib for Advanced Non-small Cell Lung Cancer. **2012**, 52, 871-877
- 142 HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases. **2012**, 13, 1457-61
- 141 Bridging Diversity. **2012**, 1-16
- 140 Predictive Markers in Lung Cancer. **2013**, 43-68
- 139 Potential of Tocotrienols in Lung Cancer. **2012**, 151-162
- 138 Six Cases of Lung Adenocarcinoma Successfully Treated Using Alternate Day Administration of Gefitinib. **2013**, 53, 25-28
- 137 Lung cancer and molecular targeted drugs. **2013**, 125, 57-66
- 136 TYPES OF DNA DAMAGE. **2013**, 115-118
- 135 [Role of diagnostic imaging in thoracic surgery]. **2013**, 69, 427-33
- 134 Alternative drug therapies are superior to epidermal growth factor receptor -targeted chemotherapeutic drug responses in non-small cell lung cancer. **2013**, 3, 10.1-10.8
- 133 Epidermal Growth Factor Receptor Testing in Lung Adenocarcinoma. **2014**, 15-22
- 132 Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. **2014**, 75-118

131 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50

130 Longcarcinom. **2014**, 117-124

129 Introduction. **2014**, 1-6

128 EGFR-Targeted Therapies in Non-small Cell Lung Cancer. **2014**, 31-66

127 Phase I Trials Today. **2015**, 661-676.e2

126 The EGFR/ERBB Receptor Family. **2015**, 107-164

125 Phase II Study of Carboplatin and Pemetrexed Followed by Gefitinib for Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive EGFR Mutation. **2015**, 06, 1214-1222

124 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79

123 Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. **2015**, 16, 5521-4

5

122 Current surgery for patients with lung cancer. **2016**, 34, 47-51

121 Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer. **2016**, 06, 17-22

120 Progress in the Research of Multi-Target Tyrosine Kinase Inhibitors. **2016**, 04, 42-54

119 Oncogenes and the Initiation and Maintenance of Tumorigenesis. **2017**, 143-157

118 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726

117 Companion Diagnostics. **2017**, 117-136

116 Design and Data Analysis of Multiregional Clinical Trials (MRCTs) Theory and Practice. **2018**, 269-286

115 Enzymatic Research Having Pharmaceutical Significance. **2018**, 141-158

114 Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. **2018**, 39, 493

¹¹³ Diagnosis and Treatment of Non-Squamous Lung Cancer Based on Molecular Tumor Testing. **2018**, 93, 266-270

¹¹² Cytology Microarray on Cell Block Preparation: A Novel Diagnostic Approach in Fluid Cytology. **2019**, 36, 79-83 2

¹¹¹ Clinical Strategies for Developing Next-Generation Cancer Precision Medicines. **2019**, 105-117

¹¹⁰ Successful Dose-reduction Therapy for Osimertinib-induced Neutropenia in EGFR-mutant Lung Adenocarcinoma: a Report of Two Cases. **2019**, 59, 46-52

¹⁰⁹ Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. **2020**, 96, 266-272 2

¹⁰⁸ Dermatological Toxicities of Targeted Therapy. **2020**, 147-164 0

¹⁰⁷ Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. **2021**,

¹⁰⁶ Pitfalls in the Design, Conduct and Analysis of Randomised Clinical Trials. **2005**, 495-503

¹⁰⁵ Molecular Staging of Non-Small-Cell Lung Cancer. **2006**, 159-176 2

¹⁰⁴ Integration of Chemotherapy in the Management of Locally Advanced Non-Small-Cell Lung Cancer. **2006**, 249-260

¹⁰³ Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer. **2006**, 261-270

¹⁰² Targeted Therapy of Non-Small-Cell Lung Cancer. **2006**, 321-334

¹⁰¹ Management of Non-Small-Cell Lung Cancer in the Elderly. **2006**, 343-351

¹⁰⁰ Non-Small-Cell Lung Cancer: Clinical Studies in Europe. **2006**, 439-450

⁹⁹ Molecular Biology of Lung Cancer. **2006**, 67-80

⁹⁸ Applications in Lung Cancer. **2006**, 231-250

⁹⁷ Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. **2008**, 291-306

⁹⁶ Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. **2008**, 307-316 1

95	Achievements in targeted therapies. 215-233	
94	Cancer Chemotherapy. 2006 , 543-557	
93	Tyrosine Kinase Inhibitors. 2007 , 477-508	
92	The Cell Cycle. 2008 , 3-32	
91	Untargeted Use of Targeted Therapy. 2008 , 227-240	
90	How to Define Treatment Success or Failure if Tumors Do Not Shrink. 2008 , 657-674	
89	Preclinical Development of Molecularly Targeted Agents in Oncology. 2008 , 707-722	0
88	[18F]Fluorodeoxyglucose Positron Emission Tomography Assessment of Response. 2007 , 103-120	1
87	Targeted Therapy in Non-Small Cell Lung Cancer. 2008 , 125-156	
86	Management of transitional cell carcinoma by targeting the epidermal growth factor receptor. 2006 , 3, 407-416	
85	Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer. 2006 , 643-670	
84	Possibilities of supportive therapy in patients with blood system tumors and malignant neoplasms. 2020 , 15, 107-127	
83	[Gefitinib for non-small cell lung cancer: a meta analysis]. 2011 , 14, 351-7	1
82	Biological response modifiers in cancer. 2006 , 8, 33	4
81	Sex-differences in lung cancer cell-types? An epidemiologic study in Ireland. 2008 , 77, 31-5	6
80	Review of erlotinib in the treatment of advanced non-small cell lung cancer. 2007 , 1, 335-46	22
79	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. 2007 , 1, 185-94	4
78	Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma. 2007 , 1, 321-4	2

77	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. 2009 , 3, 215-24	24
76	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. 2009 , 34, 554-64	15
75	The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist. 2010 , 35, 219-29	1
74	Lung cancer. 2009 , 2009,	1
73	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. 2010 , 36, 19-27	4
72	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. 2009 , 15, 213-20	8
71	Lung cancer. 2010 , 2010,	
70	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. 2010 , 10, 1-48	23
69	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. 2013 , 5, 481-96	13
68	EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. 2013 , 6, 2800-12	25
67	Relationship between uptake of a radioiodinated quinazoline derivative and radiosensitivity in non-small cell lung cancer. 2014 , 4, 293-302	1
66	Does the order of factors affect the product? Lessons learned from the TORCH trial. 2013 , 2, 50-4	
65	Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients. 2015 , 8, 16064-70	2
64	Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. 2012 , 74, 133-40	32
63	Role of epidermal growth factor receptor in lung cancer and targeted therapies. 2017 , 7, 187-202	39
62	Therapeutic value of quinazoline-based compounds in prostate cancer. 2013 , 33, 4695-700	25
61	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. 2017 , 18, 107-114	9
60	[Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib ?in Patients with Non-small Cell Lung Cancer]. 2011 , 14, 642-5	3

59	[Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer]. 2011 , 14, 245-50	2
58	[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]. 2012 , 15, 44-8	1
57	[Effectiveness of EGFR-TKIs versus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a meta-analysis]. 2015 , 18, 146-54	0
56	[EML4-ALK fusion gene in lung cancer and its biological function]. 2012 , 15, 112-6	2
55	[Efficacy of gefitinib for young patients with unknown EGFR gene mutation ?in advanced lung adenocarcinoma]. 2014 , 17, 401-5	
54	[The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro]. 2013 , 16, 1-6	1
53	[c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro]. 2013 , 16, 464-9	
52	[Graphic Evolution Witness the Development of Lung Cancer Translational Research]. 2016 , 19, 403-8	
51	Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. 2018 , 8, 2575-2589	
50	Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer. 2016 , 33, 63S-65S	
49	Soluble PD-L1 through alternative polyadenylation works as a decoy in lung cancer immunotherapy. 2021 ,	1
48	Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy.. 2021 , 16, 101309	1
47	ErbB tyrosine kinase receptor inhibitors in breast cancer treatment. 2004 , 6, 12-21	1
46	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors.. 2022 , 27,	5
45	Influence Factors of Gefitinib Concentration in Patients with Non-Small Cell Lung Cancer in Clinical Treatment. 2022 , 12, 196-205	0
44	Current Therapy and Development of Therapeutic Agents for Lung Cancer. 2022 , 100015	1
43	Targeting PI3K/Akt signal transduction for cancer therapy.. 2021 , 6, 425	27
42	AIM in Genomic Basis of Medicine: Applications. 2022 , 1087-1096	

41	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (-TKI) in -Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.. 2022 , 14, 863-873	0
40	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. 2022 , 12, 869672	3
39	EGFR Signaling in Lung Fibrosis.. 2022 , 11,	3
38	Amivantamab for the treatment of exon 20 insertion mutant non-small cell lung cancer.. 2021 , 1-14	1
37	C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway.. 2021 ,	1
36	EGFR signaling pathway as therapeutic target in human cancers.. 2022 ,	1
35	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and F-FDG Metabolic Activity in Non-Small Cell Lung Cancer.. 2022 , 12, 780186	1
34	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517	
33	Data_Sheet_1.docx. 2020 ,	
32	Data_Sheet_1.pdf. 2018 ,	
31	Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor. 2005 , 11, 397-405	34
30	Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration.. 2022 , 7, 157	0
29	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. 2022 ,	2
28	Aberrant Epidermal Growth Factor Receptor Signaling and Enhanced Sensitivity to EGFR Inhibitors in Lung Cancer. 2005 , 65, 226-235	93
27	Gefitinib reverses breast cancer resistance protein-mediated drug resistance. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1119-1125	6.1 42
26	Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer. 12,	0
25	Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.	1
24	Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1. 2022 , 153, 113373	0

23	Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 465-472	6.1	104
22	The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non-Small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2005 , 11, 1167-1173	12.9	87
21	Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 977-983	6.1	10
20	Lung Cancer Targeted Chemoradiotherapy via Dual-Stimuli Responsive Biodegradable Core-Shell Nanoparticles. <i>Pharmaceutics</i> , 2022 , 14, 1525	6.4	0
19	The Effects of Cetuximab Alone and in Combination With Radiation and/or Chemotherapy in Lung Cancer. 2005 , 11, 795-805		50
18	Panel Sequencing for Targeted Therapy Selection in Solid Tumors. 2022 ,		
17	Translational Research in Lung Cancer. 2022 ,		0
16	Targeted Therapies in Non-small Cell Lung Cancer. 2022 ,		1
15	SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. 2022 , 2022, 1-14		0
14	Changes in survival of patients with non-small cell lung cancer in Japan: an interrupted time series study.		0
13	KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner. 2023 , 66, 100908		0
12	Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). 2022 ,		0
11	Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. 2022 , 22,		0
10	The Simon's two-stage design accounting for genetic heterogeneity. 1-9		0
9	The Therapeutic Application of RBAC in Cancer. 2023 , 67-79		0
8	CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarH-like homeobox 2 axis. Publish Ahead of Print,		0
7	Historical development of EGFR-targeted therapy. 2023 , 1-11		0
6	Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. 2023 , 25, 269-280		0

- 5 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 4 Dopamine agonists and risk of lung cancer in patients with restless legs syndrome. ○
- 3 Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial. **2023**, 41, 1159-1160 ○
- 2 Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3 β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer. **2023**, 42, 1233-1246 ○
- 1 A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma. **2023**, 11, 2050313X2311595 ○